Poly(ethylene glycol) containing chemically disparate endgroups

Information

  • Patent Grant
  • 8609857
  • Patent Number
    8,609,857
  • Date Filed
    Monday, May 14, 2012
    12 years ago
  • Date Issued
    Tuesday, December 17, 2013
    10 years ago
Abstract
The present invention provides bifunctional polymers, methods of preparing the same, and intermediates thereto. These compounds are useful in a variety of applications including the PEGylation of biologically active molecules. The invention also provides methods of using said compounds and compositions thereof.
Description
FIELD OF THE INVENTION

The present invention relates to the field of polymer chemistry and more particularly to functionalized polymers, uses thereof, and intermediates thereto.


BACKGROUND OF THE INVENTION

Poly(ethylene glycol), also known as PEG, is useful in a variety of technological areas and is generally known by the formula HO—CH2CH2O—(CH2CH2O)n—CH2CH2—OH, wherein n typically ranges from about 3 to about 4000. In particular, there is great interest in utilizing PEG, and derivatives thereof, in the pharmaceutical and biomedical fields. This interest stems from the fact that PEG is nontoxic, biocompatible, non-immunogenic, soluble in water and other solvents, and is amenable to a variety of therapeutic applications including pharmaceutical formulations and drug delivery systems, among others.


One such area of interest relates to “PEGylation” or “conjugation” which refers to the modification of other molecules, especially biomolecules, using PEG and derivatives thereof. PEGylation is often utilized in order to impart the desirable characteristics of PEG to a particular molecule or biological scaffold. Such molecules or scaffolds targeted for PEGylation include proteins, dyes, peptides, hydrogels, cells, viruses, and drugs, to name but a few. In the case of drugs, the formation of PEG-drug conjugates is also of interest to improve aqueous solubility of hydrophobic drugs and improve biodistribution profiles. In addition, PEG has been utilized with a variety of natural and synthetic substrates including biological implants, medical devices, and the like. Accordingly, it would be advantageous to provide heterobifunctionalized PEG's having a variety of terminal functional groups.







DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS OF THE INVENTION
1. General Description of the Invention

In certain embodiments, the present invention provides a compound of formula I:




embedded image


  • or a salt thereof, wherein:

  • n is 10-2500;

  • R1 and R2 are each independently hydrogen, halogen, NO2, CN, N3, —N═C═O, —C(R)═NN(R)2, —P(O)(OR)2, —P(O)(X)2, a 9-30 membered crown ether, or an optionally substituted group selected from aliphatic, a 3-8 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, an 8-10 membered saturated, partially unsaturated, or aryl bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a detectable moiety;

  • each X is independently halogen;

  • each R is independently hydrogen or an optionally substituted selected from aliphatic or a 3-8 membered, saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; and

  • L1 and L2 are each independently a valence bond or a bivalent, saturated or unsaturated, straight or branched C1-12 hydrocarbon chain, wherein 0-6 methylene units of L1 and L2 are independently replaced by -Cy-, —O—, —NR—, —S—, —OC(O)—, —C(O)O—, —C(O)—, —SO—, —SO2—, —NRSO2—, —SO2NR—, —NRC(O)—, —C(O)NR—, —OC(O)NR—, or —NRC(O)O—, wherein:
    • each -Cy- is independently an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered bivalent saturated, partially unsaturated, or aryl bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur.



2. Definitions

Compounds of this invention include those described generally above, and are further illustrated by the embodiments, sub-embodiments, and species disclosed herein. As used herein, the following definitions shall apply unless otherwise indicated. For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed. Additionally, general principles of organic chemistry are described in “Organic Chemistry”, Thomas Sorrell, University Science Books, Sausalito: 1999, and “March's Advanced Organic Chemistry”, 5th Ed., Ed.: Smith, M. B. and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated by reference.


As used herein, the phrase “living polymer chain-end” refers to the terminus resulting from a polymerization reaction which maintains the ability to react further with additional monomer or with a polymerization terminator.


As used herein, the term “termination” refers to attaching a terminal group to a living polymer chain-end by reacting the living polymer chain-end with a polymerization terminator. Alternatively, the term “termination” may refer to the attachment of a terminal group to a hydroxyl end, or derivative thereof, of the polymer chain.


As used herein, the term “polymerization terminator” is used interchangeably with the term “polymerization terminating agent” and refers to compounds that react with a living polymer chain-end to afford a polymer with a terminal group. Alternatively, the term “polymerization terminator” may refer to a compound that may react with a hydroxyl end, or derivative thereof, of the polymer chain to afford a polymer with a terminal group.


As used herein, the term “polymerization initiator” refers to a compound, or anion thereof, which reacts with ethylene oxide in a manner which results in polymerization thereof. In certain embodiments, the polymerization initiator is the anion of a functional group which initiates the polymerization of ethylene oxide.


The term “aliphatic” or “aliphatic group”, as used herein, denotes a hydrocarbon moiety that may be straight-chain (i.e., unbranched), branched, or cyclic (including fused, bridging, and spiro-fused polycyclic) and may be completely saturated or may contain one or more units of unsaturation, but which is not aromatic. Unless otherwise specified, aliphatic groups contain 1-20 carbon atoms. In some embodiments, aliphatic groups contain 1-10 carbon atoms. In other embodiments, aliphatic groups contain 1-8 carbon atoms. In still other embodiments, aliphatic groups contain 1-6 carbon atoms, and in yet other embodiments aliphatic groups contain 1-4 carbon atoms. Suitable aliphatic groups include, but are not limited to, linear or branched, alkyl, alkenyl, and alkynyl groups, and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.


The term “heteroatom” means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon. This includes any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen, or; a substitutable nitrogen of a heterocyclic ring including ═N— as in 3,4-dihydro-2H-pyrrolyl, —NH— as in pyrrolidinyl, or ═N(R)— as in N-substituted pyrrolidinyl.


The term “unsaturated”, as used herein, means that a moiety has one or more units of unsaturation.


As used herein, the term “bivalent, saturated or unsaturated, straight or branched C1-12 hydrocarbon chain”, refers to bivalent alkylene, alkenylene, and alkynylene chains that are straight or branched as defined herein.


The term “aryl” used alone or as part of a larger moiety as in “aralkyl”, “aralkoxy”, or “aryloxyalkyl”, refers to monocyclic, bicyclic, and tricyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains three to seven ring members. The term “aryl” may be used interchangeably with the term “aryl ring”.


As described herein, compounds of the invention may contain “optionally substituted” moieties. In general, the term “substituted”, whether preceded by the term “optionally” or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent. Unless otherwise indicated, an “optionally substituted” group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds. The term “stable”, as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.


Suitable monovalent substituents on a substitutable carbon atom of an “optionally substituted” group are independently halogen; —(CH2)0-4—R; —(CH2)0-4R; —O—(CH2)0-4C(O)OR; —(CH2)0-4CH(OR)2; —(CH2)0-4SR; —(CH2)0-4Ph, which may be substituted with R; —(CH2)0-4O(CH2)0-1Ph which may be substituted with R; —CH═CHPh, which may be substituted with R; —NO2; —CN; —N3; —(CH2)0-4N(R)2; —(CH2)0-4N(R)C(O)R; —N(R)C(S)R; —(CH2)0-4N(R)C(O)NR2; —N(R)C(S)NR2; —(CH2)0-4N(R)C(O)OR; —N(R)N(R)C(O)R; —N(R)N(R)C(O)NR2; —N(R)N(R)C(O)OR; —(CH2)0-4C(O)R; —C(S)R; —(CH2)0-4C(O)OR; —(CH2)0-4C(O)SR; —(CH2)0-4C(O)OSiR3; —(CH2)0-4OC(O)R; —OC(O)(CH2)0-4SR—, SC(S)SR; —(CH2)0-4SC(O)R; —(CH2)0-4C(O)NR2; —C(S)NR2; —C(S)SR; —SC(S)SR, —(CH2)0-4OC(O)NR2; —C(O)N(OR)R; —C(O)C(O)R; —C(O)CH2C(O)R; —C(NOR)R; —(CH2)0-4SSR; —(CH2)0-4S(O)2R; —(CH2)0-4S(O)2OR; —(CH2)0-4S(O)2R; —S(O)2NR2; —(CH2)0-4S(O)R; —N(R)S(O)2NR2; —N(R)S(O)2R; —N(OR)R; —C(NH)NR2; —P(O)2R; —P(O)R2; —OP(O)R2; —OP(O)(OR)2; SiR3; —(C1-4 straight or branched alkylene)O—N(R)2; or —(C1-4 straight or branched alkylene)C(O)O—N(R)2, wherein each R may be substituted as defined below and is independently hydrogen, C1-6 aliphatic, —CH2Ph, —O(CH2)0-1Ph, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R, taken together with their intervening atom(s), form a 3-12-membered saturated, partially unsaturated, or aryl mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, which may be substituted as defined below.


Suitable monovalent substituents on R (or the ring formed by taking two independent occurrences of R together with their intervening atoms), are independently halogen, —(CH2)0-2R, -(haloR), —(CH2)0-2OH, —(CH2)0-2OR, —(CH2)0-2CH(OR)2; —O(haloR), —CN, —N3, —(CH2)0-2C(O)R, —(CH2)0-2C(O)OH, —(CH2)0-2C(O)OR, —(CH2)0-2SR, —(CH2)0-2SH, —(CH2)0-2NH2, —(CH2)0-2NHR, —(CH2)0-2NR2, —NO2, —SiR3, —OSiR3, —C(O)SR, —(C1-4 straight or branched alkylene)C(O)OR, or —SSR wherein each R is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently selected from C1-4 aliphatic, —CH2Ph, —O(CH2)0-1Ph, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents on a saturated carbon atom of R include ═O and ═S.


Suitable divalent substituents on a saturated carbon atom of an “optionally substituted” group include the following: ═O, ═S, ═NNR*2, ═NNHC(O)R*, ═NNHC(O)OR*, ═NNHS(O)2R*, ═NR*, ═NOR*, —O(C(R*2))2-3O—, or —S(C(R*2))2-3S—, wherein each independent occurrence of R* is selected from hydrogen, C1-6 aliphatic which may be substituted as defined below, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents that are bound to vicinal substitutable carbons of an “optionally substituted” group include: —O(CR*2)2-3O—, wherein each independent occurrence of R* is selected from hydrogen, C1-6 aliphatic which may be substituted as defined below, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. A suitable tetravalent substituent that is bound to vicinal substitutable methylene carbons of an “optionally substituted” group is the dicobalt hexacarbonyl cluster represented by




embedded image



when depicted with the methylenes which bear it.


Suitable substituents on the aliphatic group of R* include halogen, —R, -(haloR), —OH, —OR, —O(haloR), —CN, —C(O)OH, —C(O)OR, —NH2, —NHR, —NR2, or —NO2, wherein each R is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently C1-4 aliphatic, —CH2Ph, —O(CH2)0-1Ph, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.


Suitable substituents on a substitutable nitrogen of an “optionally substituted” group include —R, —NR2, —C(O)R, —C(O)OR, —C(O)C(O)R, —C(O)CH2C(O)R, —S(O)2R, —S(O)2NR2, —C(S)NR2, —C(NH)NR2, or —N(R)S(O)2R; wherein each R is independently hydrogen, C1-6 aliphatic which may be substituted as defined below, unsubstituted —OPh, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R, taken together with their intervening atom(s) form an unsubstituted 3-12-membered saturated, partially unsaturated, or aryl mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.


Suitable substituents on the aliphatic group of R are independently halogen, —R, -(haloR), —OH, —OR, —O(haloR), —CN, —C(O)OH, —C(O)OR, —NH2, —NHR, —NR2, or —NO2, wherein each R is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently C1-4 aliphatic, —CH2Ph, —O(CH2)0-1Ph, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.


Protected hydroxyl groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3rd edition, John Wiley & Sons, 1999, the entirety of which is incorporated herein by reference. Examples of suitably protected hydroxyl groups further include, but are not limited to, esters, carbonates, sulfonates allyl ethers, ethers, silyl ethers, alkyl ethers, arylalkyl ethers, and alkoxyalkyl ethers. Examples of suitable esters include formates, acetates, proprionates, pentanoates, crotonates, and benzoates. Specific examples of suitable esters include formate, benzoyl formate, chloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, p-chlorophenoxyacetate, 3-phenylpropionate, 4-oxopentanoate, 4,4-(ethylenedithio)pentanoate, pivaloate (trimethylacetate), crotonate, 4-methoxy-crotonate, benzoate, p-benzylbenzoate, 2,4,6-trimethylbenzoate. Examples of suitable carbonates include 9-fluorenylmethyl, ethyl, 2,2,2-trichloroethyl, 2-(trimethylsilyl)ethyl, 2-(phenylsulfonyl)ethyl, vinyl, allyl, and p-nitrobenzyl carbonate. Examples of suitable silyl ethers include trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, triisopropylsilyl ether, and other trialkylsilyl ethers. Examples of suitable alkyl ethers include methyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, trityl, t-butyl, and allyl ether, or derivatives thereof. Alkoxyalkyl ethers include acetals such as methoxymethyl, methylthiomethyl, (2-methoxyethoxy)methyl, benzyloxymethyl, beta-(trimethylsilyl)ethoxymethyl, and tetrahydropyran-2-yl ether. Examples of suitable arylalkyl ethers include benzyl, p-methoxybenzyl (MPM), 3,4-dimethoxybenzyl, O-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, 2- and 4-picolyl ethers.


Protected amines are well known in the art and include those described in detail in Greene (1999). Suitable mono-protected amines further include, but are not limited to, aralkylamines, carbamates, allyl amines, amides, and the like. Examples of suitable mono-protected amino moieties include t-butyloxycarbonylamino (—NHBOC), ethyloxycarbonylamino, methyloxycarbonylamino, trichloroethyloxycarbonylamino, allyloxycarbonylamino (—NHAlloc), benzyloxocarbonylamino (—NHCBZ), allylamino, benzylamino (—NHBn), fluorenylmethylcarbonyl (—NHFmoc), formamido, acetamido, chloroacetamido, dichloroacetamido, trichloroacetamido, phenylacetamido, trifluoroacetamido, benzamido, t-butyldiphenylsilyl, and the like. Suitable di-protected amines include amines that are substituted with two substituents independently selected from those described above as mono-protected amines, and further include cyclic imides, such as phthalimide, maleimide, succinimide, and the like. Suitable di-protected amines also include pyrroles and the like, 2,2,5,5-tetramethyl-[1,2,5]azadisilolidine and the like, and azide.


Protected aldehydes are well known in the art and include those described in detail in Greene (1999). Suitable protected aldehydes further include, but are not limited to, acyclic acetals, cyclic acetals, hydrazones, imines, and the like. Examples of such groups include dimethyl acetal, diethyl acetal, diisopropyl acetal, dibenzyl acetal, bis(2-nitrobenzyl)acetal, 1,3-dioxanes, 1,3-dioxolanes, semicarbazones, and derivatives thereof.


Protected carboxylic acids are well known in the art and include those described in detail in Greene (1999). Suitable protected carboxylic acids further include, but are not limited to, optionally substituted C1-6 aliphatic esters, optionally substituted aryl esters, silyl esters, activated esters, amides, hydrazides, and the like. Examples of such ester groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, benzyl, and phenyl ester, wherein each group is optionally substituted. Additional suitable protected carboxylic acids include oxazolines and ortho esters.


Protected thiols are well known in the art and include those described in detail in Greene (1999). Suitable protected thiols further include, but are not limited to, disulfides, thioethers, silyl thioethers, thioesters, thiocarbonates, and thiocarbamates, and the like. Examples of such groups include, but are not limited to, alkyl thioethers, benzyl and substituted benzyl thioethers, triphenylmethyl thioethers, and trichloroethoxycarbonyl thioester, to name but a few.


A “crown ether moiety” is the radical of a crown ether. A crown ether is a monocyclic polyether comprised of repeating units of —CH2CH2O—. Examples of crown ethers include 12-crown-4, 15-crown-5, and 18-crown-6.


Unless otherwise stated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention. Additionally, unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13C- or 14C-enriched carbon are within the scope of this invention. Such compounds are useful, for example, as analytical tools or probes in biological assays.


As used herein, the term “detectable moiety” is used interchangeably with the term “label” and relates to any moiety capable of being detected (e.g., primary labels and secondary labels). A “detectable moiety” or “label” is the radical of a detectable compound.


“Primary” labels include radioisotope-containing moieties (e.g., moieties that contain 32P, 33P, 35S, or 14C), mass-tags, and fluorescent labels, and are signal-generating reporter groups which can be detected without further modifications.


Other primary labels include those useful for positron emission tomography including molecules containing radioisotopes (e.g. 18F) or ligands with bound radioactive metals (e.g. 62Cu). In other embodiments, primary labels are contrast agents for magnetic resonance imaging such as gadolinium, gadolinium chelates, or iron oxide (e.g Fe3O4 and Fe2O3) particles. Similarly, semiconducting nanoparticles (e.g. cadmium selenide, cadmium sulfide, cadmium telluride) are useful as fluorescent labels. Other metal nanoparticles (e.g colloidal gold) also serve as primary labels.


“Secondary” labels include moieties such as biotin, or protein antigens, that require the presence of a second compound to produce a detectable signal. For example, in the case of a biotin label, the second compound may include streptavidin-enzyme conjugates. In the case of an antigen label, the second compound may include an antibody-enzyme conjugate. Additionally, certain fluorescent groups can act as secondary labels by transferring energy to another compound or group in a process of nonradiative fluorescent resonance energy transfer (FRET), causing the second compound or group to then generate the signal that is detected.


Unless otherwise indicated, radioisotope-containing moieties are optionally substituted hydrocarbon groups that contain at least one radioisotope. Unless otherwise indicated, radioisotope-containing moieties contain from 1-40 carbon atoms and one radioisotope. In certain embodiments, radioisotope-containing moieties contain from 1-20 carbon atoms and one radioisotope.


The term “mass-tag” as used herein refers to any compound that is capable of being uniquely detected by virtue of its mass using mass spectrometry (MS) detection techniques. Examples of mass-tags include electrophore release tags such as N-[3-[4′-[(p-methoxytetrafluorobenzyl)oxy]phenyl]-3-methylglyceronyl]-isonipecotic acid, 4′-[2,3,5,6-tetrafluoro-4-(pentafluorophenoxyl)]methyl acetophenone, and their derivatives. The synthesis and utility of these mass-tags is described in U.S. Pat. Nos. 4,650,750, 4,709,016, 5,360,8191, 5,516,931, 5,602,273, 5,604,104, 5,610,020, and 5,650,270. Other examples of mass-tags include, but are not limited to, nucleotides, dideoxynucleotides, oligonucleotides of varying length and base composition, oligopeptides, oligosaccharides, and other synthetic polymers of varying length and monomer composition. A large variety of organic molecules, both neutral and charged (biomolecules or synthetic compounds) of an appropriate mass range (100-2000 Daltons) may also be used as mass-tags.


The terms “fluorescent label”, “fluorescent group”, “fluorescent compound”, “fluorescent dye”, and “fluorophore”, as used herein, refer to compounds or moieties that absorb light energy at a defined excitation wavelength and emit light energy at a different wavelength. Examples of fluorescent compounds include, but are not limited to: Alexa Fluor dyes (Alexa Fluor 350, Alexa Fluor 488, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 633, Alexa Fluor 660 and Alexa Fluor 680), AMCA, AMCA-S, anthracene, BODIPY dyes (BODIPY FL, BODIPY R6G, BODIPY TMR, BODIPY TR, BODIPY 530/550, BODIPY 558/568, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY 630/650, BODIPY 650/665), carbazole, Carboxyrhodamine 6G, carboxy-X-rhodamine (ROX), Cascade Blue, Cascade Yellow, Coumarin 343, Cyanine dyes (Cy3, Cy5, Cy3.5, Cy5.5), Dansyl, Dapoxyl, Dialkylaminocoumarin, 4′,5′-Dichloro-2′,7′-dimethoxy-fluorescein, DM-NERF, Eosin, Erythrosin, Fluorescein, FAM, Hydroxycoumarin, IRDyes (IRD40, IRD 700, IRD 800), JOE, Lissamine rhodamine B, Marina Blue, Methoxycoumarin, Naphthofluorescein, Oregon Green 488, Oregon Green 500, Oregon Green 514, Pacific Blue, PyMPO, Pyrene, Rhodamine B, Rhodamine 6G, Rhodamine Green, Rhodamine Red, Rhodol Green, 2′,4′,5′,7′-Tetra-bromosulfone-fluorescein, Tetramethyl-rhodamine (TMR), Carboxytetramethylrhodamine (TAMRA), Texas Red, and Texas Red-X.


The term “substrate”, as used herein refers to any material or macromolecular complex to which a functionalized end-group of a PEG can be attached. Examples of commonly used substrates include, but are not limited to, glass surfaces, silica surfaces, plastic surfaces, metal surfaces, surfaces containing a metallic or chemical coating, membranes (e.g., nylon, polysulfone, silica), micro-beads (e.g., latex, polystyrene, or other polymer), porous polymer matrices (e.g., polyacrylamide gel, polysaccharide, polymethacrylate), and macromolecular complexes (e.g., protein, polysaccharide).


The term “targeting group”, as used herein refers to any molecule, macromolecule, or biomacromolecule which selectively binds to receptors that are over-expressed on specific cell types. Such molecules can be attached to the functionalized end-group of a PEG for cell specific delivery of proteins, viruses, DNA plasmids, oligonucleotides (e.g. siRNA, miRNA, antisense therapeutics, aptamers, etc.), drugs, dyes, and primary or secondary labels which are bound to the opposite PEG end-group. Such targeting groups include, but or not limited to monoclonal and polyclonal antibodies (e.g. IgG, IgA, IgM, IgD, IgE antibodies), sugars (e.g. mannose, mannose-6-phosphate, galactose), proteins (e.g. transferrin), oligopeptides (e.g. cyclic and acylic RGD-containing oligopedptides), oligonucleotides (e.g. aptamers), and vitamins (e.g. folate).


The term “permeation enhancer”, as used herein refers to any molecule, macromolecule, or biomacromolecule which aids in or promotes the permeation of cellular membranes and/or the membranes of intracellular compartments (e.g. endosome, lysosome, etc.) Such molecules can be attached to the functionalized end-group of a PEG to aid in the intracellular and/or cytoplasmic delivery of proteins, viruses, DNA plasmids, oligonucleotides (e.g. siRNA, miRNA, antisense therapeutics, aptamers, etc.), drugs, dyes, and primary or secondary labels which are bound to the opposite PEG end-group. Such permeation enhancers include, but are not limited to, oligopeptides containing protein transduction domains such as the HIV-1Tat peptide sequence (GRKKRRQRRR), oligoarginine (RRRRRRRRR), or penetratin (RQIKIWFQNRRMKWKK). Oligopeptides which undergo conformational changes in varying pH environments such oligohistidine (HHHHH) also promote cell entry and endosomal escape.


3. Description of Exemplary Embodiments

As defined generally above, the n group of formula I is 10-2500. In certain embodiments, the present invention provides compounds of formula I, as described above, wherein n is about 225. In other embodiments, n is about 10 to about 40. In other embodiments, n is about 40 to about 60. In other embodiments, n is about 60 to about 90. In still other embodiments, n is about 90 to about 150. In other embodiments, n is about 150 to about 200. In still other embodiments, n is about 200 to about 250. In other embodiments, n is about 300 to about 375. In other embodiments, n is about 400 to about 500. In still other embodiments, n is about 650 to about 750. In certain embodiments, n is selected from 50±10. In other embodiments, n is selected from 80±10, 115±10, 180±10, or 225±10.


According to another embodiment, the present invention provides a compound of formula I, as described above, wherein said compound has a polydispersity index (“PDI”) of about 1.0 to about 1.2. According to another embodiment, the present invention provides a compound of formula I, as described above, wherein said compound has a polydispersity index (“PDI”) of about 1.02 to about 1.05. According to yet another embodiment, the present invention provides a compound of formula I, as described above, wherein said compound has a polydispersity index (“PDI”) of about 1.05 to about 1.10. In other embodiments, said compound has a PDI of about 1.01 to about 1.03. In other embodiments, said compound has a PDI of about 1.10 to about 1.15. In still other embodiments, said compound has a PDI of about 1.15 to about 1.20.


In certain embodiments, the present invention provides a compound of formula I, as described above, wherein the R1 and R2 groups of formula I are different from each other.


In other embodiments, the present invention provides a compound of formula I, as described above, wherein only one of -L1-R1 and -L2-R2 is a hydroxyl group.


In still other embodiments, the present invention provides a compound of formula I, as described above, wherein neither of -L1-R1 and -L2-R2 is a hydroxyl group.


As defined generally above, R1 is hydrogen, halogen, NO2, CN, N3, —N═C═O, —C(R)═NN(R)2, —P(O)(OR)2, —P(O)(X)2, a 9-30-membered crown ether, or an optionally substituted group selected from aliphatic, a 3-8 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, an 8-10 membered saturated, partially unsaturated, or aryl bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a detectable moiety; wherein each R is independently hydrogen or an optionally substituted aliphatic group.


In certain embodiments, R1 is optionally substituted aliphatic. In other embodiments, R1 is an unsubstituted aliphatic. In some embodiments, said R1 moiety is an optionally substituted alkyl group. In other embodiments, said R1 moiety is an optionally substituted alkynyl or alkenyl group. Such groups include t-butyl, 5-norbornene-2-yl, octane-5-yl, —C≡CH, —CH2C≡CH, —CH2CH2C≡CH, and —CH2CH2CH2C≡CH. When said R1 moiety is a substituted aliphatic group, suitable substituents on R1 include any of CN, N3, NO2, —CO2H, —SH, —NH2, —C(O)H, —NHC(O)R, —NHC(S)R, —NHC(O)NR2, —NHC(S)NR2, —NHC(O)OR, —NHNHC(O)R, —NHNHC(O)NR2, —NHNHC(O)OR, —C(O)R, —C(S)R, —C(O)OR, —C(O)SR, —C(O)OSiR3, —OC(O)R, SC(S)SR, —SC(O)R, —C(O)N(R)2, —C(S)N(R)2, —C(S)SR, —SC(S)SR, —OC(O)N(R)2, —C(O)NHN(R)2, —C(O)N(OR)R, —C(O)C(O)RO, —C(O)CH2C(O)R, —C(NOR)R, —SSR, —S(O)2R, —S(O)2OR, —OS(O)2R, —S(O)2N(R)2, —S(O)R, —N(R)S(O)2N(R)2, —N(R)S(O)2R, —N(OR)R, —C(NH)N(R)2, —P(O)2R, —P(O)(R)2, —OP(O)(R)2, or —OP(O)(OR)2, wherein each R is as defined herein.


In other embodiments, R1 is an aliphatic group optionally substituted with any of Cl, Br, I, F, —NH2, —OH, —SH, —CO2H, —C(O)H, —C(O)(C1-6 aliphatic), —NHC(O)(C1-6 aliphatic), —NHC(O)NH2, —NHC(O)NH(C1-6 aliphatic), —NHC(S)NH—, —NHC(S)N(C1-6 aliphatic)2, —NHC(O)O(C1-6 aliphatic), —NHNH2, —NHNHC(O)(C1-6 aliphatic), —NHNHC(O)NH2, —NHNHC(O)NH(C1-6 aliphatic), —NHNHC(O)O(C1-6 aliphatic), —C(O)NH2, —C(O)NH(C1-6 aliphatic)2, —C(O)NHNH2, —C(S)N(C1-6 aliphatic)2, —OC(O)NH(C1-6 aliphatic), —C(O)C(O)(C1-6 aliphatic), —C(O)CH2C(O)(C1-6 aliphatic), —S(O)2(C1-6 aliphatic), —S(O)2O(C1-6 aliphatic), —OS(O)2(C1-6 aliphatic), —S(O)2NH(C1-6 aliphatic), —S(O)(C1-6 aliphatic), —NHS(O)2NH(C1-6 aliphatic), —NHS(O)2(C1-6 aliphatic), —P(O)2(C1-6 aliphatic), —P(O)(C1-6 aliphatic)2, —OP(O)(C1-6 aliphatic)2, or —OP(O)(OC1-6 aliphatic)2. In other embodiments, the R1 group of formula I is an optionally substituted aliphatic group having substituents as depicted in the Appendix.


In certain embodiments, the R1 group of formula I is a group suitable for Click chemistry. Click reactions tend to involve high-energy (“spring-loaded”) reagents with well-defined reaction coordinates, that give rise to selective bond-forming events of wide scope. Examples include nucleophilic trapping of strained-ring electrophiles (epoxide, aziridines, aziridinium ions, episulfonium ions), certain carbonyl reactivity (e.g., the reaction between aldehydes and hydrazines or hydroxylamines), and several cycloaddition reactions. The azide-alkyne 1,3-dipolar cycloaddition is one such reaction. Click chemistry is known in the art and one of ordinary skill in the art would recognize that certain R1 moieties of the present invention are suitable for Click chemistry.


According to one embodiment, the R1 group of formula I is an azide-containing group. According to another embodiment, the R1 group of formula I is an alkyne-containing group. In certain embodiments, the R1 group of formula I has a terminal alkyne moiety. According to another embodiment, the R1 group of formula I is an aldehyde-containing group. In certain embodiments, the R1 group of formula I has a terminal hydrazine moiety. In other embodiments, the R1 group of formula I has a terminal oxyamine moiety. In still other embodiments, the R1 group of formula I is a epoxide-containing group. In certain other embodiments, the R1 group of formula I has a terminal maleimide moiety.


In other embodiments, R1 is an optionally substituted 3-8 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, an 8-10 membered saturated, partially unsaturated, or aryl bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In certain embodiments, R1 is an optionally substituted 5-7 membered saturated or partially unsaturated ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In other embodiments, R1 is an optionally substituted phenyl ring or a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.


In certain embodiments, the R1 group of formula I is an optionally substituted aryl group. Examples include optionally substituted phenyl, optionally substituted pyridyl, optionally substituted naphthyl, optionally substituted pyrenyl, optionally substituted triazole, optionally substituted imidazole, optionally substituted phthalimide, optionally substituted tetrazole, optionally substituted furan, and optionally substituted pyran. When said R1 moiety is a substituted aryl group, suitable substituents on R1 include any of R, CN, N3, NO2, —CH3, —CH2N3, t-butyl, 5-norbornene-2-yl, octane-5-yl, —CH═CH2, —C≡CH, —CH2C≡CH, —CH2CH2C≡CH, —CH2CH2CH2C≡CH, Cl, Br, I, F, —NH2, —OH, —SH, —CO2H, —C(O)H, —CH2NH2, —CH2OH, —CH2SH, —CH2CO2H, —CH2C(O)H, —C(O)(C1-6 aliphatic), —NHC(O)(C1-6 aliphatic), —NHC(O)NH—, —NHC(O)NH(C1-6 aliphatic), —NHC(S)NH2, —NHC(S)N(C1-6 aliphatic)2, —NHC(O)O(C1-6 aliphatic), —NHNH2, —NHNHC(O)(C1-6 aliphatic), —NHNHC(O)NH2, —NHNHC(O)NH(C1-6 aliphatic), —NHNHC(O)O(C1-6 aliphatic), —C(O)NH2, —C(O)NH(C1-6 aliphatic)2, —C(O)NHNH2, —C(S)N(C1-6 aliphatic)2, —OC(O)NH(C1-6 aliphatic), —C(O)C(O)(C1-6 aliphatic), —C(O)CH2C(O)(C1-6 aliphatic), —S(O)2(C1-6 aliphatic), —S(O)2O(C1-6 aliphatic), —OS(O)2(C1-6 aliphatic), —S(O)2NH(C1-6 aliphatic), —S(O)(C1-6 aliphatic), —NHS(O)2NH(C1-6 aliphatic), —NHS(O)2(C1-6 aliphatic), —P(O)2(C1-6 aliphatic), —P(O)(C1-6 aliphatic)2, —OP(O)(C1-6 aliphatic)2, or —OP(O)(OC1-6 aliphatic)2.


Suitable substitutents on R1 further include bis-(4-ethynyl-benzyl)-amino, dipropargylamino, di-hex-5-ynyl-amino, di-pent-4-ynyl-amino, di-but-3-ynyl-amino, propargyloxy, hex-5-ynyloxy, pent-4-ynyloxy, di-but-3-ynyloxy, 2-hex-5-ynyloxy-ethyldisulfanyl, 2-pent-4-ynyloxy-ethyldisulfanyl, 2-but-3-ynyloxy-ethyldisulfanyl, 2-propargyloxy-ethyldisulfanyl, bis-benzyloxy-methyl, [1,3]dioxolan-2-yl, and [1,3]dioxan-2-yl.


In other embodiments, R1 is hydrogen.


In certain embodiments, R1 is N3.


In other embodiments, R1 is an epoxide ring.


According to certain embodiments, R1 is methyl.


According to other embodiments, R1 is —NH2.


In certain embodiments, the R1 group of formula I is a crown ether. Examples of such crown ethers include 12-crown-4, 15-crown-5, and 18-crown-6.


In still other embodiments, R1 is a detectable moiety. Detectable moieties are known in the art and include those described herein. According to one aspect of the invention, the R1 group of formula I is a fluorescent moiety. Such fluorescent moieties are well known in the art and include coumarins, quinolones, benzoisoquinolones, hostasol, and Rhodamine dyes, to name but a few. Exemplary fluorescent moieties of R1 include anthracen-9-yl, pyren-4-yl, 9-H-carbazol-9-yl, the carboxylate of rhodamine B, and the carboxylate of coumarin 343. In certain embodiments, R1 is a detectable moiety selected from:




embedded image


embedded image


wherein each wavy line indicates the point of attachment to the rest of the molecule.


In certain embodiments, R1 is —P(O)(OR)2, or —P(O)(halogen)2. According to one aspect, the present invention provides a compound of formula I, wherein R1 is —P(O)(OH)2. According to another aspect, the present invention provides a compound of formula I, wherein R1 is —P(O)(Cl)2.


According to one embodiment, the R1 group of formula I is selected from any of those depicted in Tables 1 through 25.


As defined generally above, the L1 group of formula I is a valence bond or a bivalent, saturated or unsaturated, straight or branched C1-12 hydrocarbon chain, wherein 0-6 methylene units of L1 are independently replaced by -Cy-, —O—, —NR—, —S—, —OC(O)—, —C(O)O—, —C(O)—, —SO—, —SO2—, —NRSO2—, —SO2NR—, —NRC(O)—, —C(O)NR—, —OC(O)NR—, or —NRC(O)O—, wherein each -Cy- is independently an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered bivalent saturated, partially unsaturated, or aryl bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur.


In certain embodiments, L1 is a valence bond. In other embodiments, L1 is a bivalent, saturated C1-12 hydrocarbon chain, wherein 0-6 methylene units of L1 are independently replaced by -Cy-, —O—, —NH—, —S—, —OC(O)—, —C(O)O—, —C(O)—, —C(O)NH—, or —NHC(O)—, wherein each -Cy- is independently an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered bivalent saturated, partially unsaturated, or aryl bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In still other embodiments, L1 is a bivalent, saturated C1-6 alkylene chain, wherein 0-3 methylene units of L1 are independently replaced by -Cy-, —O—, —NH—, —S—, —OC(O)—, —C(O)O—, —C(O)—, —C(O)NH—, or —NHC(O)—.


In certain embodiments, L1 is a C1-6 alkylene chain wherein one methylene unit of L1 is replaced by -Cy-. In other embodiments, L1 is -Cy- (i.e. a C1 alkylene chain wherein the methylene unit is replaced by -Cy-), wherein -Cy- is an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. According to one aspect of the present invention, -Cy- is an optionally substituted bivalent aryl group. According to another aspect of the present invention, -Cy- is an optionally substituted bivalent phenyl group. In other embodiments, -Cy- is an optionally substituted 5-8 membered bivalent, saturated carbocyclic ring. In still other embodiments, -Cy- is an optionally substituted 5-8 membered bivalent, saturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Exemplary -Cy- groups include bivalent rings selected from phenyl, pyridyl, pyrimidinyl, cyclohexyl, cyclopentyl, or cyclopropyl.


In certain embodiments, the L1 group of formula I is —O—, —S—, —NH—, or —C(O)O—. In other embodiments, the L1 group of formula I is -Cy-, —C(O)—, —C(O)NH—, —NHC(O)—, —NH—O—, or —O-Cy-CH2NH—O—. In still other embodiments, the L1 group of formula I is any of —OCH2—, —OCH2C(O)—, —OCH2CH2C(O)—, —OCH2CH2O—, —OCH2CH2S—, —OCH2CH2C(O)O—, —OCH2CH2NH—, —OCH2CH2NHC(O)—, —OCH2CH2C(O)NH—, and —NHC(O)CH2CH2C(O)O—. According to another aspect, the L1 group of formula I is any of —OCH2CH2NHC(O)CH2CH2C(O)O—, —OCH2CH2NHC(O)CH2OCH2C(O)O—, —OCH2CH2NHC(O)CH2OCH2C(O)NH—, —CH2C(O)NH—, —CH2C(O)NHNH—, or —OCH2CH2NHNH—. In certain embodiments, L1 is a C1-6 alkylene chain wherein one methylene unit of L1 is replaced by —O—. In other embodiments, L1 is —O—. Exemplary L1 groups of formula I include any of those depicted in any of Tables 1 through 25.


According to another aspect of the present invention, a functional group formed by the -L1-R1 moiety of formula I is optionally protected. Thus, in certain embodiments, the -L1-R1 moiety of formula I optionally comprises a mono-protected amine, a di-protected amine, a protected aldehyde, a protected hydroxyl, a protected carboxylic acid, or a protected thiol group.


Protected hydroxyl groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3rd edition, John Wiley & Sons, 1999, the entirety of which is incorporated herein by reference. Examples of suitably protected hydroxyl groups further include, but are not limited to, esters, carbonates, sulfonates allyl ethers, ethers, silyl ethers, alkyl ethers, arylalkyl ethers, and alkoxyalkyl ethers. Examples of suitable esters include formates, acetates, proprionates, pentanoates, crotonates, and benzoates. Specific examples of suitable esters include formate, benzoyl formate, chloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, p-chlorophenoxyacetate, 3-phenylpropionate, 4-oxopentanoate, 4,4-(ethylenedithio)pentanoate, pivaloate (trimethylacetate), crotonate, 4-methoxy-crotonate, benzoate, p-benzylbenzoate, 2,4,6-trimethylbenzoate. Examples of suitable carbonates include 9-fluorenylmethyl, ethyl, 2,2,2-trichloroethyl, 2-(trimethylsilyl)ethyl, 2-(phenylsulfonyl)ethyl, vinyl, allyl, and p-nitrobenzyl carbonate. Examples of suitable silyl ethers include trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, triisopropylsilyl ether, and other trialkylsilyl ethers. Examples of suitable alkyl ethers include methyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, trityl, t-butyl, and allyl ether, or derivatives thereof. Alkoxyalkyl ethers include acetals such as methoxymethyl, methylthiomethyl, (2-methoxyethoxy)methyl, benzyloxymethyl, beta-(trimethylsilyl)ethoxymethyl, and tetrahydropyran-2-yl ether. Examples of suitable arylalkyl ethers include benzyl, p-methoxybenzyl (MPM), 3,4-dimethoxybenzyl, O-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, 2- and 4-picolyl ethers.


Protected amines are well known in the art and include those described in detail in Greene (1999). Suitable mono-protected amines further include, but are not limited to, aralkylamines, carbamates, allyl amines, amides, and the like. Examples of suitable mono-protected amino moieties include t-butyloxycarbonylamino (—NHBOC), ethyloxycarbonylamino, methyloxycarbonylamino, trichloroethyloxycarbonylamino, allyloxycarbonylamino (—NHAlloc), benzyloxocarbonylamino (—NHCBZ), allylamino, benzylamino (—NHBn), fluorenylmethylcarbonyl (—NHFmoc), formamido, acetamido, chloroacetamido, dichloroacetamido, trichloroacetamido, phenylacetamido, trifluoroacetamido, benzamido, t-butyldiphenylsilyl, and the like. Suitable di-protected amines include amines that are substituted with two substituents independently selected from those described above as mono-protected amines, and further include cyclic imides, such as phthalimide, maleimide, succinimide, and the like. Suitable di-protected amines also include pyrroles and the like, 2,2,5,5-tetramethyl-[1,2,5]azadisilolidine and the like, and azide.


Protected aldehydes are well known in the art and include those described in detail in Greene (1999). Suitable protected aldehydes further include, but are not limited to, acyclic acetals, cyclic acetals, hydrazones, imines, and the like. Examples of such groups include dimethyl acetal, diethyl acetal, diisopropyl acetal, dibenzyl acetal, bis(2-nitrobenzyl)acetal, 1,3-dioxanes, 1,3-dioxolanes, semicarbazones, and derivatives thereof.


Protected carboxylic acids are well known in the art and include those described in detail in Greene (1999). Suitable protected carboxylic acids further include, but are not limited to, optionally substituted C1-6 aliphatic esters, optionally substituted aryl esters, silyl esters, activated esters, amides, hydrazides, and the like. Examples of such ester groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, benzyl, and phenyl ester, wherein each group is optionally substituted. Additional suitable protected carboxylic acids include oxazolines and ortho esters.


Protected thiols are well known in the art and include those described in detail in Greene (1999). Suitable protected thiols further include, but are not limited to, disulfides, thioethers, silyl thioethers, thioesters, thiocarbonates, and thiocarbamates, and the like. Examples of such groups include, but are not limited to, alkyl thioethers, benzyl and substituted benzyl thioethers, triphenylmethyl thioethers, and trichloroethoxycarbonyl thioester, to name but a few.


As defined generally above, the R2 group of formula I is hydrogen, halogen, NO2, CN, N3, —N═C═O, —C(R)═NN(R)2, —P(O)(OR)2, —P(O)(X)2, a 9-30-membered crown ether, or an optionally substituted group selected from aliphatic, a 3-8 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, an 8-10 membered saturated, partially unsaturated, or aryl bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a detectable moiety, wherein each R is independently hydrogen or an optionally substituted aliphatic group.


In certain embodiments, R2 is optionally substituted aliphatic. In other embodiments, R2 is an unsubstituted aliphatic. In some embodiments, said R2 moiety is an optionally substituted alkyl group. In other embodiments, said R2 moiety is an optionally substituted alkynyl or alkenyl group. Such groups include t-butyl, 5-norbornene-2-yl, octane-5-yl, —C≡CH, —CH2C≡CH, —CH2CH2C≡CH, and —CH2CH2CH2C≡CH. When said R2 moiety is a substituted aliphatic group, suitable substituents on R2 include any of CN, N3, NO2, —CO2H, —SH, —NH2, —C(O)H, —NHC(O)Ro, —NHC(S)R, —NHC(O)N(R)2, —NHC(S)N(R)2, —NHC(O)OR, —NHNHC(O)R, —NHNHC(O)N(R)2, —NHNHC(O)OR, —C(O)R, —C(S)R, —C(O)OR, —C(O)SR, —C(O)OSi(R)3, —OC(O)R, SC(S)SR, —SC(O)R, —C(O)NR2, —C(S)NR2, —C(S)SR; —SC(S)SR, —OC(O)N(R)2; —C(O)NHN(R)2, —C(O)N(OR)R, —C(O)C(O)R, —C(O)CH2C(O)R, —C(NOR)R, —SSR, —S(O)2R, —S(O)2OR, —OS(O)2R, —S(O)2N(R)2, —S(O)R, —N(R)S(O)2N(R)2, —N(R)S(O)2R, —N(OR)R, —C(NH)N(R)2, —P(O)2R, —P(O)(R)2, —OP(O)(R)2, or —OP(O)(OR)2, wherein each R is as defined herein.


In other embodiments, R2 is an aliphatic group optionally substituted with any of Cl, Br, I, F, —NH2, —OH, —SH, —CO2H, —C(O)H, —C(O)(C1-6 aliphatic), —NHC(O)(C1-6 aliphatic), —NHC(O)NH—, —NHC(O)NH(C1-6 aliphatic), —NHC(S)NH2, —NHC(S)N(C1-6 aliphatic)2, —NHC(O)O(C1-6 aliphatic), —NHNH2, —NHNHC(O)(C1-6 aliphatic), —NHNHC(O)NH2, —NHNHC(O)NH(C1-6 aliphatic), —NHNHC(O)O(C1-6 aliphatic), —C(O)NH2, —C(O)NH(C1-6 aliphatic)2, —C(O)NHNH2, —C(S)N(C1-6 aliphatic)2, —OC(O)NH(C1-6 aliphatic), —C(O)C(O)(C1-6 aliphatic), —C(O)CH2C(O)(C1-6 aliphatic), —S(O)2(C1-6 aliphatic), —S(O)2O(C1-6 aliphatic), —OS(O)2(C1-6 aliphatic), —S(O)2NH(C1-6 aliphatic), —S(O)(C1-6 aliphatic), —NHS(O)2NH(C1-6 aliphatic), —NHS(O)2(C1-6 aliphatic), —P(O)2(C1-6 aliphatic), —P(O)(C1-6 aliphatic)2, —OP(O)(C1-6 aliphatic)2, or —OP(O)(OC1-6 aliphatic)2. In other embodiments, the R2 group of formula I is an optionally substituted aliphatic group having substituents as depicted in any of Tables 1 through 25.


In certain embodiments, the R2 group of formula I is a group suitable for Click chemistry. Click reactions tend to involve high-energy (“spring-loaded”) reagents with well-defined reaction coordinates, that give rise to selective bond-forming events of wide scope. Examples include nucleophilic trapping of strained-ring electrophiles (epoxide, aziridines, aziridinium ions, episulfonium ions), certain carbonyl reactivity (e.g., the reaction between aldehydes and hydrazines or hydroxylamines), and several cycloaddition reactions. The azide-alkyne 1,3-dipolar cycloaddition is one such reaction. Click chemistry is known in the art and one of ordinary skill in the art would recognize that certain R2 moieties of the present invention are suitable for Click chemistry.


According to one embodiment, the R2 group of formula I is an azide-containing group. According to another embodiment, the R2 group of formula I is an alkyne-containing group. In certain embodiments, the R2 group of formula I has a terminal alkyne moiety. According to another embodiment, the R2 group of formula I is an aldehyde-containing group. In certain embodiments, the R2 group of formula I has a terminal hydrazine moiety. In other embodiments, the R2 group of formula I has a terminal oxyamine moiety. In still other embodiments, the R2 group of formula I is a epoxide-containing group. In certain other embodiments, the R2 group of formula I has a terminal maleimide moiety.


In other embodiments, R2 is an optionally substituted 3-8 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, an 8-10 membered saturated, partially unsaturated, or aryl bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In certain embodiments, R2 is an optionally substituted 3-7 membered saturated or partially unsaturated ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In other embodiments, R2 is an optionally substituted phenyl ring or a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.


In certain embodiments, the R2 group of formula I is an optionally substituted aryl group. Examples include optionally substituted phenyl, optionally substituted pyridyl, optionally substituted naphthyl, optionally substituted pyrenyl, optionally substituted triazole, optionally substituted imidazole, optionally substituted phthalimide, optionally substituted tetrazole, optionally substituted furan, and optionally substituted pyran. When said R2 moiety is a substituted aryl group, suitable substituents on R2 include R, CN, N3, NO2, —CH3, —CH2N3, t-butyl, 5-norbornene-2-yl, octane-5-yl, —CH═CH2, —C≡CH, —CH2C≡CH, —CH2CH2C≡CH, —CH2CH2CH2C≡CH, Cl, Br, I, F, —NH2, —OH, —SH, —CO2H, —C(O)H, —CH2NH2, —CH2OH, —CH2SH, —CH2CO2H, —CH2C(O)H, —C(O)(C1-6 aliphatic), —NHC(O)(C1-6 aliphatic), —NHC(O)NH—, —NHC(O)NH(C1-6 aliphatic), —NHC(S)NH—, —NHC(S)N(C1-6 aliphatic)2, —NHC(O)O(C1-6 aliphatic), —NHNH2, —NHNHC(O)(C1-6 aliphatic), —NHNHC(O)NH2, —NHNHC(O)NH(C1-6 aliphatic), —NHNHC(O)O(C1-6 aliphatic), —C(O)NH2, —C(O)NH(C1-6 aliphatic)2, —C(O)NHNH2, —C(S)N(C1-6 aliphatic)2, —OC(O)NH(C1-6 aliphatic), —C(O)C(O)(C1-6 aliphatic), —C(O)CH2C(O)(C1-6 aliphatic), —S(O)2(C1-6 aliphatic), —S(O)2O(C1-6 aliphatic), —OS(O)2(C1-6 aliphatic), —S(O)2NH(C1-6 aliphatic), —S(O)(C1-6 aliphatic), —NHS(O)2NH(C1-6 aliphatic), —NHS(O)2(C1-6 aliphatic), —P(O)2(C1-6 aliphatic), —P(O)(C1-6 aliphatic)2, —OP(O)(C1-6 aliphatic)2, or —OP(O)(OC1-6 aliphatic)2.


Suitable substitutents on R2 further include bis-(4-ethynyl-benzyl)-amino, dipropargylamino, di-hex-5-ynyl-amino, di-pent-4-ynyl-amino, di-but-3-ynyl-amino, propargyloxy, hex-5-ynyloxy, pent-4-ynyloxy, di-but-3-ynyloxy, 2-hex-5-ynyloxy-ethyldisulfanyl, 2-pent-4-ynyloxy-ethyldisulfanyl, 2-but-3-ynyloxy-ethyldisulfanyl, 2-propargyloxy-ethyldisulfanyl, bis-benzyloxy-methyl, [1,3]dioxolan-2-yl, and [1,3]dioxan-2-yl.


In other embodiments, R2 is hydrogen.


In certain embodiments, R2 is N3.


In other embodiments, R2 is an epoxide ring.


In certain embodiments, R2 is Me. In other embodiments, R2 is —NH2


In certain embodiments, the R2 group of formula I is a crown ether. Examples of such crown ethers include 12-crown-4, 15-crown-5, and 18-crown-6.


In still other embodiments, R2 is a detectable moiety. Detectable moieties are known in the art and include those described herein. According to one aspect of the invention, the R2 group of formula I is a fluorescent moiety. Such fluorescent moieties are well known in the art and include coumarins, quinolones, benzoisoquinolones, hostasol, and Rhodamine dyes, to name but a few. Exemplary fluorescent moieties of R2 include anthracen-9-yl, pyren-4-yl, 9-H-carbazol-9-yl, the carboxylate of rhodamine B, and the carboxylate of coumarin 343. In certain embodiments, R2 is a detectable moiety selected from:




embedded image


embedded image


wherein each wavy line indicates the point of attachment to the rest of the molecule.


In certain embodiments, R2 is —P(O)(OR)2, or —P(O)(X)2. According to one aspect, the present invention provides a compound of formula I, wherein R2 is —P(O)(OH)2. According to another aspect, the present invention provides a compound of formula I, wherein R2 is —P(O)(Cl)2.


In certain embodiments, the R2 group of formula I is selected from any of those depicted in any of Tables 1 through 25


As defined generally above, the L2 group of formula I is a valence bond or a bivalent, saturated or unsaturated, straight or branched C1-12 hydrocarbon chain, wherein 0-6 methylene units of L2 are independently replaced by -Cy-, —O—, —NR—, —S—, —OC(O)—, —C(O)O—, —C(O)—, —SO—, —SO2—, —NRSO2—, —SO2NR—, —NRC(O)—, —C(O)NR—, —OC(O)NR—, —NRC(O)O—, —NH—O—, or —O-Cy-CH2NH—O—, wherein each -Cy- is independently an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered bivalent saturated, partially unsaturated, or aryl bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur.


In certain embodiments, L2 is a valence bond. In other embodiments, L2 is a bivalent, saturated C1-12 alkylene chain, wherein 0-6 methylene units of L2 are independently replaced by -Cy-, —O—, —NH—, —S—, —OC(O)—, —C(O)O—, —C(O)—, —C(O)NH—, or —NHC(O)—, wherein each -Cy- is independently an optionally substituted 5-8 membered bivalent, saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered bivalent saturated, partially unsaturated, or aryl bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In still other embodiments, L2 is a bivalent, saturated C1-6 alkylene chain, wherein 0-3 methylene units of L2 are independently replaced by -Cy-, —O—, —NH—, —S—, —OC(O)—, —C(O)O—, —C(O)—, —C(O)NH—, or —NHC(O)—.


In certain embodiments, L2 is a C1-6 alkylene chain wherein one methylene unit of L2 is replaced by -Cy- or —OCy-. In other embodiments, L2 is -Cy- (i.e. a C1 alkylene chain wherein the methylene unit is replaced by -Cy-), wherein -Cy- is an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. According to one aspect of the present invention, -Cy- is an optionally substituted bivalent aryl group. According to another aspect of the present invention, -Cy- is an optionally substituted bivalent phenyl group. In other embodiments, -Cy- is an optionally substituted 5-8 membered bivalent, saturated carbocyclic ring. In still other embodiments, -Cy- is an optionally substituted 5-8 membered bivalent, saturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Exemplary -Cy- groups include bivalent rings selected from phenyl, pyridyl, pyrimidinyl, cyclohexyl, cyclopentyl, or cyclopropyl.


In certain embodiments, L2 is —O-Cy- (i.e. a C2 alkylene chain wherein one methylene unit is replaced by -Cy- and the other by —O—), wherein -Cy- is an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. According to one aspect of the present invention, -Cy- is an optionally substituted bivalent aryl group. According to another aspect of the present invention, -Cy- is an optionally substituted bivalent phenyl group. In other embodiments, -Cy- is an optionally substituted 5-8 membered bivalent, saturated carbocyclic ring. In still other embodiments, -Cy- is an optionally substituted 5-8 membered bivalent, saturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Exemplary -Cy- groups include bivalent rings selected from phenyl, pyridyl, pyrimidinyl, cyclohexyl, cyclopentyl, or cyclopropyl.


In certain embodiments, the L2 group of formula I is —O—, —S—, —NH—, or —C(O)O—. In other embodiments, the L2 group of formula I is -Cy-, —C(O)—, —C(O)NH—, —NH—O—, —O-Cy-CH2NH—O—, or —NHC(O)—. In still other embodiments, the L2 group of formula I is any of —OCH2—, —OCH2C(O)—, —OCH2CH2C(O)—, —OCH2CH2O—, —OCH2CH2S—, —OCH2CH2C(O)O—, —OCH2CH2NH—, —OCH2CH2NHC(O)—, —OCH2CH2C(O)NH—, and —NHC(O)CH2CH2C(O)O—. According to another aspect, the L2 group of formula I is any of —OCH2CH2NHC(O)CH2CH2C(O)O—, —OCH2CH2NHC(O)CH2OCH2C(O)O—, —OCH2CH2NHC(O)CH2OCH2C(O)NH—, —CH2C(O)NH—, —CH2C(O)NHNH—, or —OCH2CH2NHNH—. In other embodiments, the L2 group of formula I is —OC(O)CH2CH2CH2CH2—, —OCH2CH2—, —NHC(O)CH2CH2—, —NHC(O)CH2CH2CH2—, —OC(O)CH2CH2CH2—, —O-Cy-, —O-Cy-CH2—, —O-Cy-NH—, —O-Cy-S—, —O-Cy-C(O)—, —O-Cy-C(O)O—, —O-Cy-C(O)O-Cy-, —O-Cy-OCH2CH(CH3)C(O)O—, —O-Cy-C(O)O—, —O-Cy-OCH(CH3)CH2C(O)O—, —OCH2C(O)O—, —OCH2C(O)NH—, —OCH2O—, —OCH2S—, or —OCH2NH—. In certain embodiments, L2 is —O—. Exemplary L2 groups of formula I include any of those depicted in any of Tables 1 through 25.


According to another aspect of the present invention, a functional group formed by the -L2-R2 moiety of formula I is optionally protected. Thus, in certain embodiments, the -L2-R2 moiety of formula I optionally comprises a mono-protected amine, a di-protected amine, a protected aldehyde, a protected hydroxyl, a protected carboxylic acid, or a protected thiol group. Such groups include those described above with respect to the -L1-R1 moiety of formula I.


Exemplary compounds of formula I are set forth in the Appendix, wherein each n is as defined herein. In certain embodiments, the present invention provides any compound as depicted in the Appendix.


According to another aspect of the present invention, the R2 group of formula I is —P(O)(OR)2. Accordingly, the present invention provides a compound of formula IIa:




embedded image



or a salt thereof, wherein:


m is 10-2500;

  • Rx is hydrogen, halogen, NO2, CN, N3, —N═C═O, —C(R)═NN(R)2, —P(O)(OR)2, —P(O)(X)2, a 9-30 membered crown ether, or an optionally substituted group selected from aliphatic, a 3-8 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, an 8-10 membered saturated, partially unsaturated, or aryl bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a detectable moiety;
  • each X is independently halogen;
  • each R is independently hydrogen or an optionally substituted group selected from aliphatic or a a 3-8 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
  • Lx is a valence bond or a bivalent, saturated or unsaturated, straight or branched C1-12 hydrocarbon chain, wherein 0-6 methylene units of Lx are independently replaced by -Cy-, —O—, —NR—, —S—, —OC(O)—, —C(O)O—, —C(O)—, —SO—, —SO2—, —NRSO2—, —SO2NR—, —NRC(O)—, —C(O)NR—, —OC(O)NR—, or —NRC(O)O—, wherein:
    • each -Cy- is independently an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered bivalent saturated, partially unsaturated, or aryl bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur.


As defined generally above, the m group of formula IIa is 10-2500. In certain embodiments, the present invention provides compounds of formula IIa, as described above, wherein m is about 225. In other embodiments, m is about 10 to about 40. In other embodiments, m is about 40 to about 60. In other embodiments, m is about 60 to about 90. In still other embodiments, m is about 90 to about 150. In other embodiments, m is about 150 to about 200. In still other embodiments, m is about 200 to about 250. In other embodiments, m is about 300 to about 375. In other embodiments, m is about 400 to about 500. In still other embodiments, m is about 650 to about 750.


According to another embodiment, the present invention provides a compound of formula IIa, as described above, wherein said compound has a polydispersity index (“PDI”) of about 1.0 to about 1.2. According to another embodiment, the present invention provides a compound of formula IIa, as described above, wherein said compound has a polydispersity index (“PDI”) of about 1.02 to about 1.05. According to yet another embodiment, the present invention provides a compound of formula IIa, as described above, wherein said compound has a polydispersity index (“PDI”) of about 1.05 to about 1.10. In other embodiments, said compound has a PDI of about 1.01 to about 1.03. In other embodiments, said compound has a PDI of about 1.10 to about 1.15. In still other embodiments, said compound has a PDI of about 1.15 to about 1.20.


In other embodiments, the present invention provides a compound of formula IIa, as described above, wherein -Lx-Rx is a hydroxyl group.


As defined generally above, the Rx group of formula IIa is hydrogen, halogen, NO2, CN, N3, —N═C═O, —C(R)═NN(R)2, —P(O)(OR)2, —P(O)(halogen)2, a 9-30-membered crown ether, or an optionally substituted group selected from aliphatic, a 3-8 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, an 8-10 membered saturated, partially unsaturated, or aryl bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a detectable moiety; wherein each R is independently hydrogen or an optionally substituted aliphatic group.


In certain embodiments, the Rx group of formula IIa is optionally substituted aliphatic. In other embodiments, Rx is an unsubstituted aliphatic. In some embodiments, said Rx moiety is an optionally substituted alkyl group. In other embodiments, said Rx moiety is an optionally substituted alkynyl or alkenyl group. Such groups include t-butyl, 5-norbornene-2-yl, octane-5-yl, —C≡CH, —CH2C≡CH, —CH2CH2C≡CH, and —CH2CH2CH2C≡CH. When said Rx moiety is a substituted aliphatic group, suitable substituents on Rx include any of CN, N3, NO2, —CO2H, —SH, —NH2, —C(O)H, —NHC(O)R, —NHC(S)R, —NHC(O)NR2, —NHC(S)NR2, —NHC(O)OR, —NHNHC(O)R, —NHNHC(O)NR2, —NHNHC(O)OR, —C(O)R, —C(S)R, —C(O)OR, —C(O)SR, —C(O)OSiR3, —OC(O)R, SC(S)SR, —SC(O)R, —C(O)N(R)2, —C(S)N(R)2, —C(S)SR, —SC(S)SR, —OC(O)N(R)2, —C(O)NHN(R)2, —C(O)N(OR)R, —C(O)C(O)R, —C(O)CH2C(O)R, —C(NOR)R, —SSR, —S(O)2R, —S(O)2OR, —OS(O)2R, —S(O)2N(R)2, —S(O)R, —N(R)S(O)2N(R)2, —N(R)S(O)2R, —N(OR)R, —C(NH)N(R)2, —P(O)2R, —P(O)(R)2, —OP(O)(R)2, or —OP(O)(OR)2, wherein each R is as defined herein.


In other embodiments, Rx is an aliphatic group optionally substituted with any of Cl, Br, I, F, —NH2, —OH, —SH, —CO2H, —C(O)H, —C(O)(C1-6 aliphatic), —NHC(O)(C1-6 aliphatic), —NHC(O)NH2, —NHC(O)NH(C1-6 aliphatic), —NHC(S)NH—, —NHC(S)N(C1-6 aliphatic)2, —NHC(O)O(C1-6 aliphatic), —NHNH2, —NHNHC(O)(C1-6 aliphatic), —NHNHC(O)NH2, —NHNHC(O)NH(C1-6 aliphatic), —NHNHC(O)O(C1-6 aliphatic), —C(O)NH2, —C(O)NH(C1-6 aliphatic)2, —C(O)NHNH2, —C(S)N(C1-6 aliphatic)2, —OC(O)NH(C1-6 aliphatic), —C(O)C(O)(C1-6 aliphatic), —C(O)CH2C(O)(C1-6 aliphatic), —S(O)2(C1-6 aliphatic), —S(O)2O(C1-6 aliphatic), —OS(O)2(C1-6 aliphatic), —S(O)2NH(C1-6 aliphatic), —S(O)(C1-6 aliphatic), —NHS(O)2NH(C1-6 aliphatic), —NHS(O)2(C1-6 aliphatic), —P(O)2(C1-6 aliphatic), —P(O)(C1-6 aliphatic)2, —OP(O)(C1-6 aliphatic)2, or —OP(O)(OC1-6 aliphatic)2. In other embodiments, the Rx group of formula IIa is an optionally substituted aliphatic group having substituents as depicted in any of Tables 1 through 25.


In certain embodiments, the Rx group of formula IIa is a group suitable for Click chemistry. Click reactions tend to involve high-energy (“spring-loaded”) reagents with well-defined reaction coordinates, that give rise to selective bond-forming events of wide scope. Examples include nucleophilic trapping of strained-ring electrophiles (epoxide, aziridines, aziridinium ions, episulfonium ions), certain carbonyl reactivity (e.g., the reaction between aldehydes and hydrazines or hydroxylamines), and several cycloaddition reactions. The azide-alkyne 1,3-dipolar cycloaddition is one such reaction. Click chemistry is known in the art and one of ordinary skill in the art would recognize that certain Rx moieties of the present invention are suitable for Click chemistry.


According to one embodiment, the Rx group of formula IIa is an azide-containing group. According to another embodiment, the Rx group of formula IIa is an alkyne-containing group. In certain embodiments, the Rx group of formula IIa has a terminal alkyne moiety. According to another embodiment, the Rx group of formula IIa is an aldehyde-containing group. In certain embodiments, the Rx group of formula I has a terminal hydrazine moiety. In other embodiments, the Rx group of formula IIa has a terminal oxyamine moiety. In still other embodiments, the Rx group of formula IIa is a epoxide-containing group. In certain other embodiments, the Rx group of formula IIa has a terminal maleimide moiety.


In other embodiments, Rx is an optionally substituted 3-8 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, an 8-10 membered saturated, partially unsaturated, or aryl bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In certain embodiments, Rx is an optionally substituted 5-7 membered saturated or partially unsaturated ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In other embodiments, Rx is an optionally substituted phenyl ring or a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.


In certain embodiments, the Rx group of formula IIa is an optionally substituted aryl group. Examples include optionally substituted phenyl, optionally substituted pyridyl, optionally substituted naphthyl, optionally substituted pyrenyl, optionally substituted triazole, optionally substituted imidazole, optionally substituted phthalimide, optionally substituted tetrazole, optionally substituted furan, and optionally substituted pyran. When said Rx moiety is a substituted aryl group, suitable substituents on R1 include R, CN, N3, NO2, —CH3, —CH2N3, t-butyl, 5-norbornene-2-yl, octane-5-yl, —CH═CH2, —C≡CH, —CH2C≡CH, —CH2CH2C≡CH, —CH2CH2CH2C≡CH, Cl, Br, I, F, —NH2, —OH, —SH, —CO2H, —C(O)H, —CH2NH2, —CH2OH, —CH2SH, —CH2CO2H, —CH2C(O)H, —C(O)(C1-6 aliphatic), —NHC(O)(C1-6 aliphatic), —NHC(O)NH—, —NHC(O)NH(C1-6 aliphatic), —NHC(S)NH2, —NHC(S)N(C1-6 aliphatic)2, —NHC(O)O(C1-6 aliphatic), —NHNH2, —NHNHC(O)(C1-6 aliphatic), —NHNHC(O)NH2, —NHNHC(O)NH(C1-6 aliphatic), —NHNHC(O)O(C1-6 aliphatic), —C(O)NH2, —C(O)NH(C1-6 aliphatic)2, —C(O)NHNH2, —C(S)N(C1-6 aliphatic)2, —OC(O)NH(C1-6 aliphatic), —C(O)C(O)(C1-6 aliphatic), —C(O)CH2C(O)(C1-6 aliphatic), —S(O)2(C1-6 aliphatic), —S(O)2O(C1-6 aliphatic), —OS(O)2(C1-6 aliphatic), —S(O)2NH(C1-6 aliphatic), —S(O)(C1-6 aliphatic), —NHS(O)2NH(C1-6 aliphatic), —NHS(O)2(C1-6 aliphatic), —P(O)2(C1-6 aliphatic), —P(O)(C1-6 aliphatic)2, —OP(O)(C1-6 aliphatic)2, or —OP(O)(OC1-6 aliphatic)2.


Suitable substitutents on Rx further include bis-(4-ethynyl-benzyl)-amino, dipropargylamino, di-hex-5-ynyl-amino, di-pent-4-ynyl-amino, di-but-3-ynyl-amino, propargyloxy, hex-5-ynyloxy, pent-4-ynyloxy, di-but-3-ynyloxy, 2-hex-5-ynyloxy-ethyldisulfanyl, 2-pent-4-ynyloxy-ethyldisulfanyl, 2-but-3-ynyloxy-ethyldisulfanyl, 2-propargyloxy-ethyldisulfanyl, bis-benzyloxy-methyl, [1,3]dioxolan-2-yl, and [1,3]dioxan-2-yl.


In other embodiments, Rx is hydrogen.


In certain embodiments, Rx is N3.


In other embodiments, Rx is an epoxide ring.


In certain embodiments, Rx is methyl. In other embodiments, Rx is —NH2.


In certain embodiments, the Rx group of formula IIa is a crown ether. Examples of such crown ethers include 12-crown-4, 15-crown-5, and 18-crown-6.


In still other embodiments, Rx is a detectable moiety. Detectable moieties are known in the art and include those described herein. According to one aspect of the invention, the Rx group of formula IIa is a fluorescent moiety. Such fluorescent moieties are well known in the art and include coumarins, quinolones, benzoisoquinolones, hostasol, and Rhodamine dyes, to name but a few. Exemplary fluorescent moieties of Rx include anthracen-9-yl, pyren-4-yl, 9-H-carbazol-9-yl, the carboxylate of rhodamine B, and the carboxylate of coumarin 343. In certain embodiments, Rx is a detectable moiety selected from:




embedded image


embedded image



wherein each heavy line indicates the point of attachment to the rest of the molecule.


In certain embodiments, Rx is —P(O)(OR)2, or —P(O)(X)2. According to one aspect, the present invention provides a compound of formula IIa, wherein Rx is —P(O)(OH)2. According to another aspect, the present invention provides a compound of formula IIa, wherein Rx is —P(O)(Cl)2.


As defined generally above, the Lx group of formula IIa is a valence bond or a bivalent, saturated or unsaturated, straight or branched C1-12 hydrocarbon chain, wherein 0-6 methylene units of Lx are independently replaced by -Cy-, —O—, —NH—, —S—, —OC(O)—, —C(O)O—, —C(O)—, —SO—, —SO2—, —NHSO2—, —SO2NH—, —NHC(O)—, —C(O)NH—, —OC(O)NH—, or —NHC(O)O—, wherein -Cy- is an optionally substituted 5-8 membered bivalent, saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered bivalent saturated, partially unsaturated, or aryl bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur.


In certain embodiments, the Lx group of formula IIa is a valence bond. In other embodiments, Lx a bivalent, saturated C1-12 hydrocarbon chain, wherein 0-6 methylene units of Lx are independently replaced by -Cy-, —O—, —NH—, —S—, —OC(O)—, —C(O)O—, —C(O)—, —C(O)NH—, or —NHC(O)—, wherein -Cy- is an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered bivalent saturated, partially unsaturated, or aryl bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In still other embodiments, Lx a bivalent, saturated C1-6 alkylene chain, wherein 0-3 methylene units of Lx are independently replaced by -Cy-, —O—, —NH—, —S—, —OC(O)—, —C(O)O—, —C(O)—, —C(O)NH—, or —NHC(O)—,


In certain embodiments, Lx is -Cy- (i.e. a C1 alkylene chain wherein the methylene unit is replaced by -Cy-), wherein -Cy- is an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. According to one aspect of the present invention, -Cy- is an optionally substituted bivalent aryl group. According to another aspect of the present invention, -Cy- is an optionally substituted bivalent phenyl group. In other embodiments, -Cy- is an optionally substituted 5-8 membered bivalent, saturated carbocyclic ring. In still other embodiments, -Cy- is an optionally substituted 5-8 membered bivalent, saturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Exemplary -Cy- groups include bivalent rings selected from phenyl, pyridyl, pyrimidinyl, cyclohexyl, cyclopentyl, or cyclopropyl.


In certain embodiments, the Lx group of formula IIa is —O—, —S—, —NH—, or —C(O)O—. In other embodiments, the Lx group of formula IIa is -Cy-, —C(O)—, —C(O)NH—, —NHC(O)—, —NH—O—, or —O-Cy-CH2NH—O—. In still other embodiments, the Lx group of formula IIa is any of —OCH2—, —OCH2C(O)—, —OCH2CH2C(O)—, —OCH2CH2O—, —OCH2CH2S—, —OCH2CH2C(O)O—, —OCH2CH2NH—, —OCH2CH2NHC(O)—, —OCH2CH2C(O)NH—, and —NHC(O)CH2CH2C(O)O—. According to another aspect, the Lx group of formula IIa is any of —OCH2CH2NHC(O)CH2CH2C(O)O—, —OCH2CH2NHC(O)CH2OCH2C(O)O—, —OCH2CH2NHC(O)CH2OCH2C(O)NH—, —CH2C(O)NH—, —CH2C(O)NHNH—, or —OCH2CH2NHNH—. Exemplary Lx groups of formula IIa include any of those depicted in any of Tables 1 through 25.


According to another aspect of the present invention, a functional group formed by the -L-Rx moiety of formula IIa is optionally protected. Thus, in certain embodiments, the -Lx-Rx moiety of formula IIa optionally comprises a mono-protected amine, a di-protected amine, a protected aldehyde, a protected hydroxyl, a protected carboxylic acid, or a protected thiol group. Such groups include those described above with respect to the -L1-R1 moiety of formula I.


According to yet another aspect of the present invention, the R2 group of formula I is —P(O)(X)2. Accordingly, the present invention provides a compound of formula IIb:




embedded image



or a salt thereof, wherein:


m is 10-2500;


each X is independently halogen;

  • Rx is hydrogen, halogen, NO2, CN, N3, —N═C═O, —C(R)═NN(R)2, —P(O)(OR)2, —P(O)(X)2, a 9-30 membered crown ether, or an optionally substituted group selected from aliphatic, a 3-8 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, an 8-10 membered saturated, partially unsaturated, or aryl bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a detectable moiety;
  • each R is independently hydrogen or an optionally substituted group selected from aliphatic or a a 3-8 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
  • Lx is a valence bond or a bivalent, saturated or unsaturated, straight or branched C1-12 hydrocarbon chain, wherein 0-6 methylene units of Lx are independently replaced by -Cy-, —O—, —NR—, —S—, —OC(O)—, —C(O)O—, —C(O)—, —SO—, —SO2—, —NRSO2—, —SO2NR—, —NRC(O)—, —C(O)NR—, —OC(O)NR—, or —NRC(O)O—, wherein:
    • each -Cy- is independently an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered bivalent saturated, partially unsaturated, or aryl bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur.


As defined generally above, the m group of formula IIb is 10-2500. In certain embodiments, the present invention provides compounds of formula IIb, as described above, wherein m is about 225. In other embodiments, m is about 10 to about 40. In other embodiments, m is about 40 to about 60. In other embodiments, m is about 60 to about 90. In still other embodiments, m is about 90 to about 150. In other embodiments, m is about 150 to about 200. In still other embodiments, m is about 200 to about 250. In other embodiments, m is about 300 to about 375. In other embodiments, m is about 400 to about 500. In still other embodiments, m is about 650 to about 750.


According to another embodiment, the present invention provides a compound of formula IIb, as described above, wherein said compound has a polydispersity index (“PDI”) of about 1.0 to about 1.2. According to another embodiment, the present invention provides a compound of formula IIb, as described above, wherein said compound has a polydispersity index (“PDI”) of about 1.02 to about 1.05. According to yet another embodiment, the present invention provides a compound of formula IIb, as described above, wherein said compound has a polydispersity index (“PDI”) of about 1.05 to about 1.10. In other embodiments, said compound has a PDI of about 1.01 to about 1.03. In other embodiments, said compound has a PDI of about 1.10 to about 1.15. In still other embodiments, said compound has a PDI of about 1.15 to about 1.20.


In other embodiments, the present invention provides a compound of formula IIb, as described above, wherein -L-Rx is a hydroxyl group.


As defined generally above, the Rx of formula IIb is hydrogen, halogen, NO2, CN, N3, —N═C═O, —C(R)═NN(R)2, —P(O)(OR)2, —P(O)(X)2, a 9-30-membered crown ether, or an optionally substituted group selected from aliphatic, a 3-8 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, an 8-10 membered saturated, partially unsaturated, or aryl bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a detectable moiety; wherein each R is independently hydrogen or an optionally substituted aliphatic group.


In certain embodiments, the Rx group of formula lib is optionally substituted aliphatic. In other embodiments, Rx is an unsubstituted aliphatic. In some embodiments, said Rx moiety is an optionally substituted alkyl group. In other embodiments, said Rx moiety is an optionally substituted alkynyl or alkenyl group. Such groups include t-butyl, 5-norbornene-2-yl, octane-5-yl, —C≡CH, —CH2C≡CH, —CH2CH2C≡CH, and —CH2CH2CH2C≡CH. When said Rx moiety is a substituted aliphatic group, suitable substituents on Rx include any of CN, N3, NO2, —CO2H, —SH, —NH2, —C(O)H, —NHC(O)R, —NHC(S)R, —NHC(O)NR2, —NHC(S)NR2, —NHC(O)OR, —NHNHC(O)R, —NHNHC(O)NR2, —NHNHC(O)OR, —C(O)R, —C(S)R, —C(O)OR, —C(O)SR, —C(O)OSiR3, —OC(O)R, SC(S)SR, —SC(O)R, —C(O)N(R)2, —C(S)N(R)2, —C(S)SR, —SC(S)SR, —OC(O)N(R)2, —C(O)NHN(R)2, —C(O)N(OR)R, —C(O)C(O)R, —C(O)CH2C(O)R, —C(NOR)R, —SSR, —S(O)2R, —S(O)2OR, —OS(O)2R, —S(O)2N(R)2, —S(O)R, —N(R)S(O)2N(R)2, —N(R)S(O)2R, —N(OR)R, —C(NH)N(R)2, —P(O)2R, —P(O)(R)2, —OP(O)(R)2, or —OP(O)(OR)2, wherein each R is as defined herein.


In other embodiments, Rx is an aliphatic group optionally substituted with any of Cl, Br, I, F, —NH2, —OH, —SH, —CO2H, —C(O)H, —C(O)(C1-6 aliphatic), —NHC(O)(C1-6 aliphatic), —NHC(O)NH2, —NHC(O)NH(C1-6 aliphatic), —NHC(S)NH—, —NHC(S)N(C1-6 aliphatic)2, —NHC(O)O(C1-6 aliphatic), —NHNH2, —NHNHC(O)(C1-6 aliphatic), —NHNHC(O)NH2, —NHNHC(O)NH(C1-6 aliphatic), —NHNHC(O)O(C1-6 aliphatic), —C(O)NH2, —C(O)NH(C1-6 aliphatic)2, —C(O)NHNH2, —C(S)N(C1-6 aliphatic)2, —OC(O)NH(C1-6 aliphatic), —C(O)C(O)(C1-6 aliphatic), —C(O)CH2C(O)(C1-6 aliphatic), —S(O)2(C1-6 aliphatic), —S(O)2O(C1-6 aliphatic), —OS(O)2(C1-6 aliphatic), —S(O)2NH(C1-6 aliphatic), —S(O)(C1-6 aliphatic), —NHS(O)2NH(C1-6 aliphatic), —NHS(O)2(C1-6 aliphatic), —P(O)2(C1-6 aliphatic), —P(O)(C1-6 aliphatic)2, —OP(O)(C1-6 aliphatic)2, or —OP(O)(OC1-6 aliphatic)2. In other embodiments, the Rx group of formula IIb is an optionally substituted aliphatic group having substituents as depicted for R1 in any of Tables 1 through 25.


In certain embodiments, the Rx group of formula IIb is a group suitable for Click chemistry. Click reactions tend to involve high-energy (“spring-loaded”) reagents with well-defined reaction coordinates, that give rise to selective bond-forming events of wide scope. Examples include nucleophilic trapping of strained-ring electrophiles (epoxide, aziridines, aziridinium ions, episulfonium ions), certain carbonyl reactivity (e.g., the reaction between aldehydes and hydrazines or hydroxylamines), and several cycloaddition reactions. The azide-alkyne 1,3-dipolar cycloaddition is one such reaction. Click chemistry is known in the art and one of ordinary skill in the art would recognize that certain Rx moieties of the present invention are suitable for Click chemistry.


According to one embodiment, the Rx group of formula IIb is an azide-containing group. According to another embodiment, the Rx group of formula IIb is an alkyne-containing group. In certain embodiments, the Rx group of formula IIb has a terminal alkyne moiety. According to another embodiment, the Rx group of formula IIb is an aldehyde-containing group. In certain embodiments, the Rx group of formula IIb has a terminal hydrazine moiety. In other embodiments, the Rx group of formula IIb has a terminal oxyamine moiety. In still other embodiments, the Rx group of formula IIb is a epoxide-containing group. In certain other embodiments, the Rx group of formula IIb has a terminal maleimide moiety.


In other embodiments, Rx is an optionally substituted 5-8 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, an 8-10 membered saturated, partially unsaturated, or aryl bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In certain embodiments, Rx is an optionally substituted 5-7 membered saturated or partially unsaturated ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In other embodiments, Rx is an optionally substituted phenyl ring or a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.


In certain embodiments, the Rx group of formula IIb is an optionally substituted aryl group. Examples include optionally substituted phenyl, optionally substituted pyridyl, optionally substituted naphthyl, optionally substituted pyrenyl, optionally substituted triazole, optionally substituted imidazole, optionally substituted phthalimide, optionally substituted tetrazole, optionally substituted furan, and optionally substituted pyran. When said Rx moiety is a substituted aryl group, suitable substituents on Rx include R, CN, N3, NO2, —CH3, —CH2N3, t-butyl, 5-norbornene-2-yl, octane-5-yl, —CH═CH2, —C≡CH, —CH2C≡CH, —CH2CH2C≡CH, —CH2CH2CH2C≡CH, Cl, Br, I, F, —NH2, —OH, —SH, —CO2H, —C(O)H, —CH2NH2, —CH2OH, —CH2SH, —CH2CO2H, —CH2C(O)H, —C(O)(C1-6 aliphatic), —NHC(O)(C1-6 aliphatic), —NHC(O)NH—, —NHC(O)NH(C1-6 aliphatic), —NHC(S)NH2, —NHC(S)N(C1-6 aliphatic)2, —NHC(O)O(C1-6 aliphatic), —NHNH2, —NHNHC(O)(C1-6 aliphatic), —NHNHC(O)NH2, —NHNHC(O)NH(C1-6 aliphatic), —NHNHC(O)O(C1-6 aliphatic), —C(O)NH2, —C(O)NH(C1-6 aliphatic)2, —C(O)NHNH2, —C(S)N(C1-6 aliphatic)2, —OC(O)NH(C1-6 aliphatic), —C(O)C(O)(C1-6 aliphatic), —C(O)CH2C(O)(C1-6 aliphatic), —S(O)2(C1-6 aliphatic), —S(O)2O(C1-6 aliphatic), —OS(O)2(C1-6 aliphatic), —S(O)2NH(C1-6 aliphatic), —S(O)(C1-6 aliphatic), —NHS(O)2NH(C1-6 aliphatic), —NHS(O)2(C1-6 aliphatic), —P(O)2(C1-6 aliphatic), —P(O)(C1-6 aliphatic)2, —OP(O)(C1-6 aliphatic)2, or —OP(O)(OC1-6 aliphatic)2.


Suitable substitutents on Rx further include bis-(4-ethynyl-benzyl)-amino, dipropargylamino, di-hex-5-ynyl-amino, di-pent-4-ynyl-amino, di-but-3-ynyl-amino, propargyloxy, hex-5-ynyloxy, pent-4-ynyloxy, di-but-3-ynyloxy, 2-hex-5-ynyloxy-ethyldisulfanyl, 2-pent-4-ynyloxy-ethyldisulfanyl, 2-but-3-ynyloxy-ethyldisulfanyl, 2-propargyloxy-ethyldisulfanyl, bis-benzyloxy-methyl, [1,3]dioxolan-2-yl, and [1,3]dioxan-2-yl.


In other embodiments, Rx is hydrogen.


In certain embodiments, Rx is N3.


In certain embodiments, Rx is an epoxide ring.


In certain embodiments, Rx is methyl. In other embodiments, Rx is —NH2.


In certain embodiments, the Rx group of formula IIb is a crown ether. Examples of such crown ethers include 12-crown-4, 15-crown-5, and 18-crown-6.


In still other embodiments, Rx is a detectable moiety. Detectable moieties are known in the art and include those described herein. According to one aspect of the invention, the Rx group of formula IIb is a fluorescent moiety. Such fluorescent moieties are well known in the art and include coumarins, quinolones, benzoisoquinolones, hostasol, and Rhodamine dyes, to name but a few. Exemplary fluorescent moieties of Rx include anthracen-9-yl, pyren-4-yl, 9-H-carbazol-9-yl, the carboxylate of rhodamine B, and the carboxylate of coumarin 343. In certain embodiments, Rx is a detectable moiety selected from:




embedded image


embedded image



wherein each wavy line indicates the point of attachment to the rest of the molecule.


In certain embodiments, Rx is —P(O)(OR)2, or —P(O)(X)2. According to one aspect, the present invention provides a compound of formula IIb, wherein Rx is —P(O)(OH)2. According to another aspect, the present invention provides a compound of formula IIb, wherein Rx is —P(O)(Cl)2.


As defined generally above, the Lx group of formula IIb is a valence bond or a bivalent, saturated or unsaturated, straight or branched C1-12 hydrocarbon chain, wherein 0-6 methylene units of Lx are independently replaced by -Cy-, —O—, —NH—, —S—, —OC(O)—, —C(O)O—, —C(O)—, —SO—, —SO2—, —NHSO2—, —SO2NH—, —NHC(O)—, —C(O)NH—, —OC(O)NH—, or —NHC(O)O—, wherein -Cy- is an optionally substituted 5-8 membered bivalent, saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered bivalent saturated, partially unsaturated, or aryl bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur.


In certain embodiments, the Lx group of formula IIb is a valence bond. In other embodiments, Lx a bivalent, saturated C1-12 hydrocarbon chain, wherein 0-6 methylene units of Lx are independently replaced by -Cy-, —O—, —NH—, —S—, —OC(O)—, —C(O)O—, —C(O)—, —C(O)NH—, or —NHC(O)—, wherein -Cy- is an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered bivalent saturated, partially unsaturated, or aryl bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In still other embodiments, Lx a bivalent, saturated C1-6 alkylene chain, wherein 0-3 methylene units of Lx are independently replaced by -Cy-, —O—, —NH—, —S—, —OC(O)—, —C(O)O—, —C(O)—, —C(O)NH—, or —NHC(O)—.


In certain embodiments, Lx is -Cy- (i.e. a C1 alkylene chain wherein the methylene unit is replaced by -Cy-), wherein -Cy- is an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. According to one aspect of the present invention, -Cy- is an optionally substituted bivalent aryl group. According to another aspect of the present invention, -Cy- is an optionally substituted bivalent phenyl group. In other embodiments, -Cy- is an optionally substituted 5-8 membered bivalent, saturated carbocyclic ring. In still other embodiments, -Cy- is an optionally substituted 5-8 membered bivalent, saturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Exemplary -Cy- groups include bivalent rings selected from phenyl, pyridyl, pyrimidinyl, cyclohexyl, cyclopentyl, or cyclopropyl.


In certain embodiments, the Lx group of formula IIb is —O—, —S—, —NH—, or —C(O)O—. In other embodiments, the Lx group of formula IIb is -Cy-, —C(O)—, —C(O)NH—, —NHC(O)—, —NH—O—, or —O-Cy-CH2NH—O—. In still other embodiments, the Lx group of formula IIb is any of —OCH2—, —OCH2C(O)—, —OCH2CH2C(O)—, —OCH2CH2O—, —OCH2CH2S—, —OCH2CH2C(O)O—, —OCH2CH2NH—, —OCH2CH2NHC(O)—, —OCH2CH2C(O)NH—, and —NHC(O)CH2CH2C(O)O—. According to another aspect, the Lx group of formula IIb is any of —OCH2CH2NHC(O)CH2CH2C(O)O—, —OCH2CH2NHC(O)CH2OCH2C(O)O—, —OCH2CH2NHC(O)CH2OCH2C(O)NH—, —CH2C(O)NH—, —CH2C(O)NHNH—, or —OCH2CH2NHNH—. Exemplary Lx groups of formula IIb include any of those depicted in any of Tables 1 through 25.


According to another aspect of the present invention, a functional group formed by the -Lx-Rx moiety of formula IIb is optionally protected. Thus, in certain embodiments, the -Lx-Rx moiety of formula IIb optionally comprises a mono-protected amine, a di-protected amine, a protected aldehyde, a protected hydroxyl, a protected carboxylic acid, or a protected thiol group. Such groups include those described above with respect to the -L1-R1 moiety of formula I.


Exemplary compounds of formula IIa and IIb are set forth in Tables 1 through 25.


According to another embodiment, the present invention provides a compound of either of formulae IIIa or IIIb:




embedded image



or a salt thereof, wherein n, L1, L2, R1, and R2 are as defined above and described in classes and subclasses herein, singly and in combination.


Yet another embodiment relates to a compound of either of formulae IVa or IVb:




embedded image



or a salt thereof, wherein n, L1, L2, R2, and R2 are as defined above and described in classes and subclasses herein, singly and in combination.


Yet another embodiment relates to a compound of either of formulae Va or Vb:




embedded image



or a salt thereof, wherein n, L1, L2, R1, and R2 are as defined above and described in classes and subclasses herein, singly and in combination.


In certain embodiments, the present invention provides a compound of either of formulae VIa or VIb:




embedded image



or a salt thereof, wherein n, L1, L2, R1, and R2 are as defined above and described in classes and subclasses herein, singly and in combination.


In other embodiments, the present invention provides a compound of either of formulae VIIa or VIIb:




embedded image



or a salt thereof, wherein n, L1, L2, R1, and R2 are as defined above and described in classes and subclasses herein, singly and in combination.


In still other embodiments, the present invention provides a compound of either of formulae VIIIa or VIIIb:




embedded image



or a salt thereof, wherein n, L1, L2, R1, and R2 are as defined above and described in classes and subclasses herein, singly and in combination.


According to another embodiment, the present invention provides a compound of either of formulae IXa or IXb:




embedded image



or a salt thereof, wherein n, L1, L2, R1, and R2 are as defined above and described in classes and subclasses herein, singly and in combination.


According to yet another embodiment, the present invention provides a compound of either of formulae Xa or Xb:




embedded image



or a salt thereof, wherein n, L1, L2, R1, and R2 are as defined above and described in classes and subclasses herein, singly and in combination.


In certain embodiments, the present invention provides a compound of any of formulae XIa, XIb, XIc, XId, XIe, or XIf:




embedded image



or a salt thereof, wherein n, L1, L2, R1, and R2 are as defined above and described in classes and subclasses herein, singly and in combination.


In certain embodiments, the present invention provides a compound as described herein, wherein R1 is a C1-6 aliphatic substituted with —CO2H. Exemplary compounds include those set forth in Table 1, wherein n is as described in classes and subclasses herein. In certain embodiments, n is selected from 50±10. In other embodiments, n is selected from 80±10, 115±10, 180±10, or 225±10.









TABLE 1







Exemplary Compounds




embedded image














#
Ra
Rb












1


embedded image




embedded image







2


embedded image




embedded image







3


embedded image




embedded image







4


embedded image




embedded image







5


embedded image




embedded image







6


embedded image




embedded image







7


embedded image




embedded image







8


embedded image




embedded image







9


embedded image




embedded image







10


embedded image




embedded image







11


embedded image




embedded image







12


embedded image




embedded image







13


embedded image




embedded image







14


embedded image




embedded image







15


embedded image




embedded image







16


embedded image




embedded image







17


embedded image




embedded image







18


embedded image




embedded image







19


embedded image




embedded image







20


embedded image




embedded image







21


embedded image




embedded image







22


embedded image




embedded image







23


embedded image




embedded image







24


embedded image




embedded image







25


embedded image




embedded image







26


embedded image




embedded image











In certain embodiments, the present invention provides a compound as described herein, wherein R1 is a C1-6 aliphatic substituted with oxazolinyl. Exemplary compounds include those set forth in Table 2, wherein n is as described in classes and subclasses herein. In certain embodiments, n is selected from 50±10. In other embodiments, n is selected from 80±10, 115±10, 180±10, or 225±10.









TABLE 2







Exemplary Compounds




embedded image
















#
Ra
Rb






27


embedded image




embedded image








28


embedded image




embedded image








29


embedded image




embedded image











In certain embodiments, the present invention provides a compound as described herein, wherein L1 is a C1-6 alkylene wherein two methylene units of L1 are substituted with —C(O)NH— and —C(O)O—, and R1 is hydrogen. Exemplary compounds include those set forth in Table 3, wherein n is as described in classes and subclasses herein. In certain embodiments, n is selected from 50±10. In other embodiments, n is selected from 80±10, 115±10, 180±10, or 225±10.









TABLE 3







Exemplary Compounds




embedded image














#
Ra
Rb





30


embedded image




embedded image







31


embedded image




embedded image







32


embedded image




embedded image







33


embedded image




embedded image







34


embedded image




embedded image







35


embedded image




embedded image







36


embedded image




embedded image







37


embedded image




embedded image







38


embedded image




embedded image







39


embedded image




embedded image







40


embedded image




embedded image







41


embedded image




embedded image







42


embedded image




embedded image







43


embedded image




embedded image







44


embedded image




embedded image







45


embedded image




embedded image







46


embedded image




embedded image







47


embedded image




embedded image







48


embedded image




embedded image







49


embedded image




embedded image







50


embedded image




embedded image







51


embedded image




embedded image







52


embedded image




embedded image







53


embedded image




embedded image







54


embedded image




embedded image







55


embedded image




embedded image







56


embedded image




embedded image







57


embedded image




embedded image







58


embedded image




embedded image







59


embedded image




embedded image







60


embedded image




embedded image







61


embedded image




embedded image







62


embedded image




embedded image







63


embedded image




embedded image







64


embedded image




embedded image







65


embedded image




embedded image







66


embedded image




embedded image







67


embedded image




embedded image







68


embedded image




embedded image







69


embedded image




embedded image







70


embedded image




embedded image







71


embedded image




embedded image







72


embedded image




embedded image







73


embedded image




embedded image







74


embedded image




embedded image







75


embedded image




embedded image







76


embedded image




embedded image







77


embedded image




embedded image







78


embedded image




embedded image







79


embedded image




embedded image







80


embedded image




embedded image







81


embedded image




embedded image







82


embedded image




embedded image







83


embedded image




embedded image











In certain embodiments, the present invention provides a compound as described herein, wherein L1 is a C1-6 alkylene wherein three methylene units of L1 are substituted with —C(O)NH—, —O—, and —C(O)O—, and R1 is hydrogen. Exemplary compounds include those set forth in Table 4, wherein n is as described in classes and subclasses herein. In certain embodiments, n is selected from 50±10. In other embodiments, n is selected from 80±10, 115±10, 180±10, or 225±10.









TABLE 4







Exemplary Compounds




embedded image














#
Ra
Rb












84


embedded image




embedded image







85


embedded image




embedded image







86


embedded image




embedded image







87


embedded image




embedded image







88


embedded image




embedded image







89


embedded image




embedded image







90


embedded image




embedded image







91


embedded image




embedded image







92


embedded image




embedded image







93


embedded image




embedded image







94


embedded image




embedded image







95


embedded image




embedded image







96


embedded image




embedded image







97


embedded image




embedded image







98


embedded image




embedded image







99


embedded image




embedded image







100


embedded image




embedded image







101


embedded image




embedded image







102


embedded image




embedded image







103


embedded image




embedded image







104


embedded image




embedded image







105


embedded image




embedded image







106


embedded image




embedded image







107


embedded image




embedded image







108


embedded image




embedded image







109


embedded image




embedded image







110


embedded image




embedded image











In certain embodiments, the present invention provides a compound as described herein, wherein L1 is —O— and R1 is hydrogen. Exemplary compounds include those set forth in Table 5, wherein n is as described in classes and subclasses herein. In certain embodiments, n is selected from 50±10. In other embodiments, n is selected from 80±10, 115±10, 180±10, or 225±10.









TABLE 5







Exemplary Compounds




embedded image











#
Ra
Rb








111


embedded image




embedded image







112


embedded image




embedded image







113


embedded image




embedded image







114


embedded image




embedded image







115


embedded image




embedded image







116


embedded image




embedded image







117


embedded image




embedded image







118


embedded image




embedded image







119


embedded image




embedded image







120


embedded image




embedded image







121


embedded image




embedded image







122


embedded image




embedded image







123


embedded image




embedded image







124


embedded image




embedded image







125


embedded image




embedded image







126


embedded image




embedded image







127


embedded image




embedded image







128


embedded image




embedded image







129


embedded image




embedded image







130


embedded image




embedded image







131


embedded image




embedded image







132


embedded image




embedded image







133


embedded image




embedded image







134


embedded image




embedded image







135


embedded image




embedded image







136


embedded image




embedded image







137


embedded image




embedded image











In certain embodiments, the present invention provides a compound as described herein, wherein L1 is —C(O)— and R1 is hydrogen. Exemplary compounds include those set forth in Table 6, wherein n is as described in classes and subclasses herein. In certain embodiments, n is selected from 50±10. In other embodiments, n is selected from 80±10, 115±10, 180±10, or 225±10.









TABLE 6







Exemplary Compounds




embedded image











#
Ra
Rb





138


embedded image




embedded image







139


embedded image




embedded image







140


embedded image




embedded image







141


embedded image




embedded image







142


embedded image




embedded image







143


embedded image




embedded image







144


embedded image




embedded image







145


embedded image




embedded image







146


embedded image




embedded image







147


embedded image




embedded image







148


embedded image




embedded image







149


embedded image




embedded image







150


embedded image




embedded image







151


embedded image




embedded image







152


embedded image




embedded image







153


embedded image




embedded image







154


embedded image




embedded image







155


embedded image




embedded image







156


embedded image




embedded image







157


embedded image




embedded image







158


embedded image




embedded image







159


embedded image




embedded image







160


embedded image




embedded image







161


embedded image




embedded image







162


embedded image




embedded image







163


embedded image




embedded image







164


embedded image




embedded image







165


embedded image




embedded image











In certain embodiments, the present invention provides a compound as described herein, wherein -L1-R1 moiety of formula I comprises a protected aldehyde. Exemplary compounds include those set forth in Table 7, wherein n is as described in classes and subclasses herein. In certain embodiments, n is selected from 50±10. In other embodiments, n is selected from 80±10, 115±10, 180±10, or 225±10.









TABLE 7







Exemplary Compounds




embedded image











#
Ra
Rb





166


embedded image




embedded image







167


embedded image




embedded image







168


embedded image




embedded image







169


embedded image




embedded image







170


embedded image




embedded image







171


embedded image




embedded image







172


embedded image




embedded image







173


embedded image




embedded image







174


embedded image




embedded image







175


embedded image




embedded image







176


embedded image




embedded image







177


embedded image




embedded image







178


embedded image




embedded image







179


embedded image




embedded image







180


embedded image




embedded image







181


embedded image




embedded image







182


embedded image




embedded image







183


embedded image




embedded image







184


embedded image




embedded image







185


embedded image




embedded image











In certain embodiments, the present invention provides a compound as described herein, wherein the R1 moiety of formula I comprises an acetylene moiety. Exemplary compounds include those set forth in Table 8, wherein n is as described in classes and subclasses herein. In certain embodiments, n is selected from 50±10. In other embodiments, n is selected from 80±10, 115±10, 180±10, or 225±10.









TABLE 8







Exemplary Compounds




embedded image











#
Ra
Rb





186


embedded image




embedded image







187


embedded image




embedded image







188


embedded image




embedded image







189


embedded image




embedded image







190


embedded image




embedded image







191


embedded image




embedded image







192


embedded image




embedded image







193


embedded image




embedded image







194


embedded image




embedded image







195


embedded image




embedded image







196


embedded image




embedded image







197


embedded image




embedded image







198


embedded image




embedded image







199


embedded image




embedded image











In certain embodiments, the present invention provides a compound as described herein, wherein the R1 moiety of formula I comprises a protected acetylene moiety. Exemplary compounds include those set forth in Table 9, wherein n is as described in classes and subclasses herein. In certain embodiments, n is selected from 50±10. In other embodiments, n is selected from 80±10, 115±10, 180±10, or 225±10.









TABLE 9







Exemplary Compounds




embedded image











#
Ra
Rb





200


embedded image




embedded image







201


embedded image




embedded image







202


embedded image




embedded image







203


embedded image




embedded image







204


embedded image




embedded image







205


embedded image




embedded image







206


embedded image




embedded image







207


embedded image




embedded image







208


embedded image




embedded image







209


embedded image




embedded image







210


embedded image




embedded image







211


embedded image




embedded image







212


embedded image




embedded image







213


embedded image




embedded image







214


embedded image




embedded image







215


embedded image




embedded image







216


embedded image




embedded image







217


embedded image




embedded image







218


embedded image




embedded image







219


embedded image




embedded image







220


embedded image




embedded image







221


embedded image




embedded image







222


embedded image




embedded image







223


embedded image




embedded image







224


embedded image




embedded image







225


embedded image




embedded image







226


embedded image




embedded image







227


embedded image




embedded image











In certain embodiments, the present invention provides a compound as described herein, wherein the R1 moiety of formula I comprises —NH2. Exemplary compounds include those set forth in Table 10, wherein n is as described in classes and subclasses herein. In certain embodiments, n is selected from 50±10. In other embodiments, n is selected from 80±10, 115±10, 180±10, or 225±10.


Table 10. Exemplary Compounds









TABLE 10







Exemplary Compounds




embedded image











#
Ra
Rb





228


embedded image




embedded image







229


embedded image




embedded image







230


embedded image




embedded image







231


embedded image




embedded image







232


embedded image




embedded image







233


embedded image




embedded image







234


embedded image




embedded image







235


embedded image




embedded image







236


embedded image




embedded image







237


embedded image




embedded image







238


embedded image




embedded image







239


embedded image




embedded image







240


embedded image




embedded image







241


embedded image




embedded image







242


embedded image




embedded image







243


embedded image




embedded image







244


embedded image




embedded image







245


embedded image




embedded image







246


embedded image




embedded image







248


embedded image




embedded image







249


embedded image




embedded image







250


embedded image




embedded image







251


embedded image




embedded image







252


embedded image




embedded image







253


embedded image




embedded image







254


embedded image




embedded image







255


embedded image




embedded image











In certain embodiments, the present invention provides a compound as described herein, wherein the R1 moiety of formula I comprises a protected amino group. Exemplary compounds include those set forth in Table 11, wherein n is as described in classes and subclasses herein. In certain embodiments, n is selected from 50±10. In other embodiments, n is selected from 80±10, 115±10, 180±10, or 225±10.









TABLE 11







Exemplary Compounds




embedded image











#
Ra
Rb





256


embedded image




embedded image







257


embedded image




embedded image







258


embedded image




embedded image







259


embedded image




embedded image







260


embedded image




embedded image







261


embedded image




embedded image







262


embedded image




embedded image







263


embedded image




embedded image







264


embedded image




embedded image







265


embedded image




embedded image







266


embedded image




embedded image







267


embedded image




embedded image







268


embedded image




embedded image







269


embedded image




embedded image







270


embedded image




embedded image







271


embedded image




embedded image







272


embedded image




embedded image







273


embedded image




embedded image







274


embedded image




embedded image







275


embedded image




embedded image







276


embedded image




embedded image







277


embedded image




embedded image







278


embedded image




embedded image







279


embedded image




embedded image







280


embedded image




embedded image







281


embedded image




embedded image







282


embedded image




embedded image







283


embedded image




embedded image







284


embedded image




embedded image







285


embedded image




embedded image







286


embedded image




embedded image







287


embedded image




embedded image







288


embedded image




embedded image







289


embedded image




embedded image







290


embedded image




embedded image











In certain embodiments, the present invention provides a compound as described herein, wherein the R1 moiety of formula I comprises an azide. Exemplary compounds include those set forth in Table 12, wherein n is as described in classes and subclasses herein. In certain embodiments, n is selected from 50±10. In other embodiments, n is selected from 80±10, 115±10, 180±10, or 225±10.









TABLE 12







Exemplary Compounds




embedded image











#
Ra
Rb





291


embedded image




embedded image







292


embedded image




embedded image







293


embedded image




embedded image







294


embedded image




embedded image







295


embedded image




embedded image







296


embedded image




embedded image







297


embedded image




embedded image







298


embedded image




embedded image







299


embedded image




embedded image







300


embedded image




embedded image







301


embedded image




embedded image







302


embedded image




embedded image







303


embedded image




embedded image







304


embedded image




embedded image







305


embedded image




embedded image







306


embedded image




embedded image







307


embedded image




embedded image







308


embedded image




embedded image







309


embedded image




embedded image







310


embedded image




embedded image







311


embedded image




embedded image







312


embedded image




embedded image







313


embedded image




embedded image







314


embedded image




embedded image







315


embedded image




embedded image







316


embedded image




embedded image







317


embedded image




embedded image







318


embedded image




embedded image







319


embedded image




embedded image







320


embedded image




embedded image







321


embedded image




embedded image











In certain embodiments, the present invention provides a compound as described herein, wherein the R1 moiety of formula I comprises an epoxide. Exemplary compounds include those set forth in Table 13, wherein n is as described in classes and subclasses herein. In certain embodiments, n is selected from 50±10. In other embodiments, n is selected from 80±10, 115±10, 180±10, or 225±10.









TABLE 13







Exemplary Compounds




embedded image














#
Ra
Rb





322


embedded image




embedded image







323


embedded image




embedded image







324


embedded image




embedded image







325


embedded image




embedded image







326


embedded image




embedded image







327


embedded image




embedded image







328


embedded image




embedded image







329


embedded image








330


embedded image




embedded image







331


embedded image




embedded image







332


embedded image




embedded image







333


embedded image




embedded image







334


embedded image




embedded image







335


embedded image




embedded image







336


embedded image




embedded image







337


embedded image




embedded image







338


embedded image




embedded image







339


embedded image




embedded image







340


embedded image




embedded image







341


embedded image




embedded image







342


embedded image




embedded image







343


embedded image




embedded image







344


embedded image




embedded image











In certain embodiments, the present invention provides a compound as described herein, wherein the R1 moiety of formula I comprises a detectable moiety. Exemplary compounds include those set forth in Table 14, wherein n is as described in classes and subclasses herein. In certain embodiments, n is selected from 50±10. In other embodiments, n is selected from 80±10, 115±10, 180±10, or 225±10.









TABLE 14







Exemplary Compounds




embedded image














#
Ra
Rb





345


embedded image




embedded image







346


embedded image




embedded image







347


embedded image




embedded image







348


embedded image




embedded image







349


embedded image




embedded image







350


embedded image




embedded image







351


embedded image




embedded image







352


embedded image




embedded image







353


embedded image




embedded image







354


embedded image




embedded image







355


embedded image




embedded image







356


embedded image




embedded image







357


embedded image




embedded image







358


embedded image




embedded image







359


embedded image




embedded image







360


embedded image




embedded image







361


embedded image




embedded image







362


embedded image




embedded image







363


embedded image




embedded image







364


embedded image




embedded image







365


embedded image




embedded image







366


embedded image




embedded image







367


embedded image




embedded image







368


embedded image




embedded image







369


embedded image




embedded image







370


embedded image




embedded image







371


embedded image




embedded image







372


embedded image




embedded image







373


embedded image




embedded image







374


embedded image




embedded image







375


embedded image




embedded image







376


embedded image




embedded image







377


embedded image




embedded image







378


embedded image




embedded image











In certain embodiments, the present invention provides a compound as described herein, wherein the L1 moiety of formula I is a C1-8 membered alkylene wherein three methylene units of L1 are replaced by —C(O)NH—, —NHC(O)—, and —NH—, and R1 is hydrogen. Exemplary compounds include those set forth in Table 15, wherein n is as described in classes and subclasses herein. In certain embodiments, n is selected from 50±10. In other embodiments, n is selected from 80±10, 115±10, 180±10, or 225±10.









TABLE 15







Exemplary Compounds




embedded image














#
Ra
Rb





379


embedded image




embedded image







380


embedded image




embedded image







381


embedded image




embedded image







382


embedded image




embedded image







383


embedded image




embedded image







384


embedded image




embedded image







385


embedded image




embedded image







386


embedded image




embedded image







387


embedded image




embedded image







388


embedded image




embedded image







389


embedded image




embedded image







390


embedded image




embedded image







391


embedded image




embedded image







392


embedded image




embedded image







393


embedded image




embedded image







394


embedded image




embedded image







395


embedded image




embedded image







396


embedded image




embedded image







397


embedded image




embedded image







398


embedded image




embedded image







399


embedded image




embedded image







400


embedded image




embedded image







401


embedded image




embedded image







402


embedded image




embedded image







403


embedded image




embedded image







404


embedded image




embedded image







405


embedded image




embedded image







406


embedded image




embedded image











In certain embodiments, the present invention provides a compound as described herein, wherein the L1 moiety of formula I is a C1-10 membered alkylene wherein four methylene units of L1 are replaced by —C(O)NH—, —NHC(O)—, —O—, and —NH—, and R1 is hydrogen. Exemplary compounds include those set forth in Table 16, wherein n is as described in classes and subclasses herein. In certain embodiments, n is selected from 50±10. In other embodiments, n is selected from 80±10, 115±10, 180±10, or 225±10.









TABLE 16







Exemplary Compounds




embedded image














#
Ra
Rb





407


embedded image




embedded image







408


embedded image




embedded image







409


embedded image




embedded image







410


embedded image




embedded image







411


embedded image




embedded image







412


embedded image




embedded image







413


embedded image




embedded image







414


embedded image




embedded image







415


embedded image




embedded image







416


embedded image




embedded image







417


embedded image




embedded image







418


embedded image




embedded image







419


embedded image




embedded image







420


embedded image




embedded image







421


embedded image




embedded image







422


embedded image




embedded image







423


embedded image




embedded image







424


embedded image




embedded image







425


embedded image




embedded image







426


embedded image




embedded image







427


embedded image




embedded image







428


embedded image




embedded image







429


embedded image




embedded image







430


embedded image




embedded image







431


embedded image




embedded image







432


embedded image




embedded image







433


embedded image




embedded image







434


embedded image




embedded image











In certain embodiments, the present invention provides a compound as described herein, wherein the L1 moiety of formula I is a C1-6 membered alkylene wherein two methylene units of L1 are replaced by —C(O)NH— and —NH—, and R1 is hydrogen. Exemplary compounds include those set forth in Table 17, wherein n is as described in classes and subclasses herein. In certain embodiments, n is selected from 50±10. In other embodiments, n is selected from 80±10, 115±10, 180±10, or 225±10.









TABLE 17







Exemplary Compounds




embedded image














#
Ra
Rb





435


embedded image




embedded image







436


embedded image




embedded image







437


embedded image




embedded image







438


embedded image




embedded image







439


embedded image




embedded image







440


embedded image




embedded image







441


embedded image




embedded image







442


embedded image




embedded image







443


embedded image




embedded image







444


embedded image




embedded image







445


embedded image




embedded image







446


embedded image




embedded image







447


embedded image




embedded image







448


embedded image




embedded image







449


embedded image




embedded image







450


embedded image




embedded image







451


embedded image




embedded image







452


embedded image




embedded image







453


embedded image




embedded image







454


embedded image




embedded image







455


embedded image




embedded image







456


embedded image




embedded image







457


embedded image




embedded image







458


embedded image




embedded image







459


embedded image




embedded image







460


embedded image




embedded image







461


embedded image




embedded image







462


embedded image




embedded image











In certain embodiments, the present invention provides a compound as described herein, wherein the L1 moiety of formula I is a C1-6 membered alkylene wherein two methylene units of L1 are replaced by —NH— and R1 is hydrogen. Exemplary compounds include those set forth in Table 18, wherein n is as described in classes and subclasses herein. In certain embodiments, n is selected from 50±10. In other embodiments, n is selected from 80±10, 115±10, 180±10, or 225±10.









TABLE 18







Exemplary Compounds




embedded image














#
Ra
Rb





463


embedded image




embedded image







464


embedded image




embedded image







465


embedded image




embedded image







466


embedded image




embedded image







467


embedded image




embedded image







468


embedded image




embedded image







469


embedded image




embedded image







470


embedded image




embedded image







471


embedded image




embedded image







472


embedded image




embedded image







473


embedded image




embedded image







474


embedded image




embedded image







475


embedded image




embedded image







476


embedded image




embedded image







477


embedded image




embedded image







478


embedded image




embedded image







479


embedded image




embedded image







480


embedded image




embedded image







481


embedded image




embedded image







482


embedded image




embedded image







483


embedded image




embedded image







484


embedded image




embedded image







485


embedded image




embedded image







486


embedded image




embedded image







487


embedded image




embedded image







488


embedded image




embedded image







489


embedded image




embedded image







490


embedded image




embedded image







491


embedded image




embedded image











In certain embodiments, the present invention provides a compound as described herein, wherein the L1 moiety of formula I is a C1-6 membered alkylene wherein two methylene units of L1 are replaced by —O— and —NH—, and R1 is hydrogen. Exemplary compounds include those set forth in Table 19, wherein n is as described in classes and subclasses herein. In certain embodiments, n is selected from 50±10. In other embodiments, n is selected from 80±10, 115±10, 180±10, or 225±10.









TABLE 19







Exemplary Compounds




embedded image














#
Ra
Rb





492


embedded image




embedded image







493


embedded image




embedded image







494


embedded image




embedded image







495


embedded image




embedded image







496


embedded image




embedded image







497


embedded image




embedded image







498


embedded image




embedded image







499


embedded image




embedded image







500


embedded image




embedded image







501


embedded image




embedded image







502


embedded image




embedded image







503


embedded image




embedded image







504


embedded image




embedded image







505


embedded image




embedded image







506


embedded image




embedded image







507


embedded image




embedded image







508


embedded image




embedded image







509


embedded image




embedded image







510


embedded image




embedded image







511


embedded image




embedded image







512


embedded image




embedded image







513


embedded image




embedded image







514


embedded image




embedded image







515


embedded image




embedded image







516


embedded image




embedded image







517


embedded image




embedded image







518


embedded image




embedded image







519


embedded image




embedded image











In certain embodiments, the present invention provides a compound as described herein, wherein the L1 moiety of formula I is a C1-6 membered alkylene wherein one methylene unit of L1 is replaced by —O— and R1 is —CN. Exemplary compounds include those set forth in Table 20, wherein n is as described in classes and subclasses herein. In certain embodiments, n is selected from 50±10. In other embodiments, n is selected from 80±10, 115±10, 180±10, or 225±10.









TABLE 20







Exemplary Compounds




embedded image














#
Ra
Rb





520


embedded image




embedded image







521


embedded image




embedded image







522


embedded image




embedded image







523


embedded image




embedded image







524


embedded image




embedded image







525


embedded image




embedded image







526


embedded image




embedded image







527


embedded image




embedded image







528


embedded image




embedded image







529


embedded image




embedded image







530


embedded image




embedded image







531


embedded image




embedded image







532


embedded image




embedded image







533


embedded image




embedded image







534


embedded image




embedded image







535


embedded image




embedded image







536


embedded image




embedded image







537


embedded image




embedded image







538


embedded image




embedded image







539


embedded image




embedded image







540


embedded image




embedded image







541


embedded image




embedded image







542


embedded image




embedded image







543


embedded image




embedded image







544


embedded image




embedded image











In certain embodiments, the present invention provides a compound as described herein, wherein the L1 moiety of formula I is a C1-6 membered alkylene wherein one methylene unit of L1 is replaced by —S— and R1 is —H. Exemplary compounds include those set forth in Table 21, wherein n is as described in classes and subclasses herein. In certain embodiments, n is selected from 50±10. In other embodiments, n is selected from 80±10, 115±10, 180±10, or 225±10.









TABLE 21







Exemplary Compounds




embedded image














#
Ra
Rb





545


embedded image




embedded image







546


embedded image




embedded image







547


embedded image




embedded image







548


embedded image




embedded image







549


embedded image




embedded image







550


embedded image




embedded image







551


embedded image




embedded image







552


embedded image




embedded image







553


embedded image




embedded image







554


embedded image




embedded image







555


embedded image




embedded image







556


embedded image




embedded image







557


embedded image




embedded image







558


embedded image




embedded image







559


embedded image




embedded image







560


embedded image




embedded image







561


embedded image




embedded image







562


embedded image




embedded image







563


embedded image




embedded image







564


embedded image




embedded image







565


embedded image




embedded image







566


embedded image




embedded image







567


embedded image




embedded image







568


embedded image




embedded image







569


embedded image




embedded image







570


embedded image




embedded image







571


embedded image




embedded image







572


embedded image




embedded image











In certain embodiments, the present invention provides a compound as described herein, wherein R1 is a protected thiol moiety. Exemplary compounds include those set forth in Table 22, wherein n is as described in classes and subclasses herein. In certain embodiments, n is selected from 50±10. In other embodiments, n is selected from 80±10, 115±10, 180±10, or 225±10.









TABLE 22







Exemplary Compounds




embedded image
















#
Ra
Rb







573


embedded image




embedded image









574


embedded image




embedded image









575


embedded image




embedded image









576


embedded image




embedded image












In certain embodiments, the present invention provides a compound as described herein, wherein R1 is C1-6 aliphatic and, in certain embodiments, alkenyl. Exemplary compounds include those set forth in Table 23, wherein n is as described in classes and subclasses herein. In certain embodiments, n is selected from 50±10. In other embodiments, n is selected from 80±10, 115±10, 180±10, or 225±10.









TABLE 23







Exemplary Compounds




embedded image














#
Ra
Rb





577


embedded image




embedded image







578


embedded image




embedded image







579


embedded image




embedded image







580


embedded image




embedded image











In certain embodiments, the present invention provides a compound as described herein, wherein R1 is a bicyclic, partially unsaturated 7 membered ring. Exemplary compounds include those set forth in Table 24, wherein n is as described in classes and subclasses herein. In certain embodiments, n is selected from 50±10. In other embodiments, n is selected from 80±10, 115±10, 180±10, or 225±10.









TABLE 24







Exemplary Compounds




embedded image














#
Ra
Rb





581


embedded image




embedded image







582


embedded image




embedded image







583


embedded image




embedded image







584


embedded image




embedded image











In certain embodiments, the present invention provides a compound selected from those set forth in Table 25, wherein n is as described in classes and subclasses herein. In certain embodiments, n is selected from 50±10. In other embodiments, n is selected from 80±10, 115±10, 180±10, or 225±10.









TABLE 25







Exemplary Compounds




embedded image














#
Ra
Rb





585


embedded image




embedded image







586


embedded image




embedded image







587


embedded image




embedded image







588


embedded image




embedded image







589


embedded image




embedded image







590


embedded image




embedded image







591


embedded image




embedded image







592


embedded image




embedded image







593


embedded image




embedded image







594


embedded image




embedded image







595


embedded image




embedded image







596


embedded image




embedded image







597


embedded image




embedded image







598


embedded image




embedded image







599


embedded image




embedded image







600


embedded image




embedded image







601


embedded image




embedded image











4. General Methods of Providing the Present Compounds

Compounds of this invention may be prepared in general by synthetic methods known to those skilled in the art for analogous compounds and as illustrated by the general schemes and the preparative examples that follow. In certain embodiments, compounds of the present invention are prepared by methods as described in detail in U.S. patent application entitled “Heterobifunctional poly(ethylene glycol) and Uses Thereof” filed Oct. 24, 2005, and given Ser. No. 11/256,735, the entirety of which is hereby incorporated herein by reference.




embedded image


Scheme I above shows a general method for preparing compounds of the present invention. At step (a), the polymerization initiator is treated with a suitable base to form 2. A variety of bases are suitable for the reaction at step (a). Such bases include, but are not limited to, potassium naphthalenide, diphenylmethyl potassium, triphenylmethyl potassium, and potassium hydride. At step (b), the resulting anion is treated with ethylene oxide to form the polymer 3. Polymer 3 can be transformed at step (d) to a compound of formula I directly by terminating the living polymer chain-end of 3 with a suitable polymerization terminator to afford a compound of formula I. Alternatively, polymer 3 may be quenched at step (c) to form the hydroxyl compound 4. Compound 4 is then derivatized to afford a compound of formula I by methods known in the art.


One of ordinary skill in the art will recognize that the derivatization of a compound of formula 4 to form a compound of formula I may be achieved in a single step or via a multi-step process. For example, the hydroxyl group of formula 4 can be converted to a suitable leaving group which is then displaced by a nucleophile to form a compound of formula I. Suitable leaving groups are well known in the art, e.g., see, “Advanced Organic Chemistry,” Jerry March, 5th Ed., pp. 351-357, John Wiley and Sons, N.Y. Such leaving groups include, but are not limited to, halogen, alkoxy, sulphonyloxy, optionally substituted alkylsulphonyloxy, optionally substituted alkenylsulfonyloxy, optionally substituted arylsulfonyloxy, and diazonium moieties. Examples of suitable leaving groups include chloro, iodo, bromo, fluoro, methanesulfonyloxy (mesyloxy), tosyloxy, triflyloxy, nitro-phenylsulfonyloxy (nosyloxy), and bromo-phenylsulfonyloxy (brosyloxy).


According to an alternate embodiment, the suitable leaving group may be generated in situ within a reaction medium. For example, a leaving group may be generated in situ from a precursor of that compound wherein said precursor contains a group readily replaced by said leaving group in situ.


Derivatization of the hydroxyl group of formula 4 can be achieved using methods known to one of ordinary skill in the art to obtain a variety of compounds. For example, said hydroxyl group may be transformed to a protected hydroxyl group, or, alternatively, to a suitable leaving group. Hydroxyl protecting groups are well known and include those described above and herein. Such transformations are known to one skilled in the art and include, among others, those described herein.


An exemplary transformation includes coupling of the hydroxyl group of formula 4 with an acid to form an ester thereof. Once of ordinary skill in the art would recognize that this transformation would result in compounds of formula I wherein L2 is a bivalent, saturated or unsaturated, straight or branched C1-12 alkylene chain, as defined and described herein, wherein the terminal methylene group is replaced by —C(O)O—. Such coupling reactions are well known in the art. In certain embodiments, the coupling is achieved with a suitable coupling reagent. Such reagents are well known in the art and include, for example, DCC and EDC, among others. In other embodiments, the carboxylic acid moiety is activated for use in the coupling reaction. Such activation includes formation of an acyl halide, use of a Mukaiyama reagent, and the like. These methods, and others, are known to one of ordinary skill in the art, e.g., see, “Advanced Organic Chemistry,” Jerry March, 5th Ed., pp. 351-357, John Wiley and Sons, N.Y.


In certain embodiments, the R2-L2- group of formula I is incorporated at either of steps (b) or (e) by derivatization of the hydroxyl group of formula 4 via Mitsunobu coupling. The Mitsunobu reaction is a mild method for achieving formal substitution of the hydroxyl group using azodicarboxylic esters/amides and triphenylphosphine (TPP) or trialkylphosphines or phosphites. In addition, other azo compounds have been developed as alternatives to the traditional azodicarboxylic esters diethylazodicarboxylate (DEAD) and diisopropylazodicarboxylate (DIAD). These include dibenzyl azodicarboxylate (DBAD), N,N,N′,N′-tetramethylazodicarbonamide (TMAD), and dipiperidyl azodicarboxylate (DPAD). Mitsunobu coupling provides access to terminal groups including, but not limited to, halides, azide, amines, esters, ethers, thioethers and isothiocyanates. Accordingly, it will be appreciated that a variety of compounds of formula I are obtained by the derivatization of the hydroxyl group of formula 4 by Mitsunobu reaction.


In certain embodiments, the polymerization terminating agent is one that is capable of Mistunobu coupling. These include optionally substituted phenols, optionally substituted thiophenols, cyclic imides, carboxylic acids, azide, and other reagents capable of Mitsunobu coupling. Such Mitsunobu terminating agents include, but are not limited to, those set forth in Table 26, below.









TABLE 26





Representative Mitsunobu Polymerization Terminating Agents


















embedded image


M-1







embedded image


M-2







embedded image


M-3







embedded image


M-4







embedded image


M-5







embedded image


M-6







embedded image


M-7







embedded image


M-8







embedded image


M-9







embedded image


M-10







embedded image


M-11







embedded image


M-12







embedded image


M-13







embedded image


M-14







embedded image


M-15







embedded image


M-16







embedded image


M-17







embedded image


M-18







embedded image


M-19







embedded image


M-20







embedded image


M-21







embedded image


M-22







embedded image


M-23







embedded image


M-24







embedded image


M-25







embedded image


M-26







embedded image


M-27







embedded image


M-28







embedded image


M-29







embedded image


M-30







embedded image


M-31







embedded image


M-32







embedded image


M-33







embedded image


M-34







embedded image


M-35







embedded image


M-36







embedded image


M-37







embedded image


M-38







embedded image


M-39







embedded image


M-40







embedded image


M-41







embedded image


M-42







embedded image


M-43







embedded image


M-44







embedded image


M-45







embedded image


M-46







embedded image


M-47







embedded image


M-48







embedded image


M-49







embedded image


M-50







embedded image


M-51







embedded image


M-52







embedded image


M-53







embedded image


M-54







embedded image


M-55







embedded image


M-56







embedded image


M-57







embedded image


M-58







embedded image


M-59





NaBr
M-60


Nal
M-61


H—N3
M-62


Na—N3
M-63







embedded image


M-64







embedded image


M-65







embedded image


M-66







embedded image


M-67







embedded image


M-68







embedded image


M-69







embedded image


M-70







embedded image


M-71







embedded image


M-72







embedded image


M-73







embedded image


M-74







embedded image


M-75







embedded image


M-76







embedded image


M-77







embedded image


M-78







embedded image


M-79







embedded image


M-80







embedded image


M-81







embedded image


M-82







embedded image


M-83







embedded image


M-84







embedded image


M-85







embedded image


M-86









In other embodiments, the R2-L2- group of formula I is incorporated by derivatization of the hydroxyl group of formula 4 via anhydride coupling. One of ordinary skill in the art would recognize that anhydride polymerization terminating agents containing an azide, an aldehyde, a protected hydroxyl, an alkyne, and other groups, may be used to incorporate said azide, said aldehyde, said protected hydroxyl, said alkyne, and other groups into the R2-L2- group of compounds of formula I. It will also be appreciated that such anhydride polymerization terminating agents are also suitable for terminating the living polymer chain-end of a compound of formula 3. Such anhydride polymerization terminating agents include, but are not limited to, those set forth in Table 27, below.









TABLE 27





Representative Anhydride Polymerization Terminating Agents


















embedded image


A-1







embedded image


A-2







embedded image


A-3







embedded image


A-4







embedded image


A-5







embedded image


A-6







embedded image


A-7







embedded image


A-8







embedded image


A-9







embedded image


A-10







embedded image


A-11







embedded image


A-12







embedded image


A-13









In other embodiments, the R2-L2-group of formula I is incorporated by derivatization of the hydroxyl group of formula 4 via reaction with a polymerization terminating agent having a suitable leaving group. It will also be appreciated that such polymerization terminating agents are also suitable for terminating the living polymer chain-end of a compound of formula 3. Examples of these polymerization terminating agents include, but are not limited to, those set forth in Table 28, below.









TABLE 28





Representative Polymerization Terminating Agents


















embedded image


L-1







embedded image


L-2







embedded image


L-3







embedded image


L-4







embedded image


L-5







embedded image


L-6







embedded image


L-7







embedded image


L-8







embedded image


L-9







embedded image


L-10







embedded image


L-11







embedded image


L-12







embedded image


L-13







embedded image


L-14







embedded image


L-15







embedded image


L-16







embedded image


L-17







embedded image


L-18







embedded image


L-19







embedded image


L-20







embedded image


L-21







embedded image


L-22







embedded image


L-23







embedded image


L-24







embedded image


L-25







embedded image


L-26







embedded image


L-27







embedded image


L-28







embedded image


L-29







embedded image


L-30







embedded image


L-31







embedded image


L-32







embedded image


L-33







embedded image


L-34







embedded image


L-35







embedded image


L-36







embedded image


L-37







embedded image


L-38







embedded image


L-39







embedded image


L-40







embedded image


L-41







embedded image


L-42







embedded image


L-43







embedded image


L-44










wherein each L is a suitable leaving group as defined above and in classes and subclasses as described above and herein.


One of ordinary skill in the art will recognize that certain of the terminating groups depicted in Tables 26, 27, and 28 comprise protected functional groups. It will be appreciated that these protecting groups are optionally removed to form compounds of the present invention. Methods for the deprotection of functional groups are well known to one of ordinary skill in the art and include those described in detail in Greene (1999).


Although certain exemplary embodiments are depicted and described above and herein, it will be appreciated that compounds of the invention can be prepared according to the methods described generally above using appropriate starting materials by methods generally available to one of ordinary skill in the art. Additional embodiments are exemplified in more detail herein.


5. Uses, Methods, and Compositions

As discussed above, the present invention provides bifunctional PEG's, intermediates thereto, and methods of preparing the same. Such functionalized PEG's are useful for a variety of purposes in the pharmaceutical and biomedical fields. Such uses include using the bifunctional PEG's of the present invention in the process of PEGylating other molecules or substrates. Accordingly, another embodiment of the present invention provides a molecule or substrate conjugation with a compound of the present invention. The term “PEGylation,” as used herein, is used interchangeably with the term “conjugation”. Thus, the product of PEGylation is known as a “conjugate.”


For example, U.S. Pat. No. 6,797,257 describes imaging agents prepared by PEGylating gadolinium oxide albumin microspheres. U.S. Pat. Nos. 6,790,823 and 6,764,853 describe the PEGylation of proteins by covalently bonding through amino acid residues via a reactive group, such as, a free amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be bound. Amino acid residues having a free amino group include lysine residues. N-terminal amino acid residues; i.e. those having a free carboxyl group, include aspartic acid residues, glutamic acid residues, and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecule(s).


Another aspect of the invention provides a method of PEGylating a primary or secondary label, a dye, or another detectable moiety for biosensors, bioassays, biorecognition, detection, proteomics, genomics, microarray, and other molecular biological applications. Thus, in certain embodiments, the present invention provides a detectable moiety conjugated with a compound of the present invention. Such PEGylation may be carried out by covalent linking of one PEG functionality to the detectable moiety or through coordination of a PEG functionality (e.g. thiol, amine, alcohol, carboxylic acid) to the detectable moiety. The opposite PEG end group can be further linked to targeting groups, permeation enhancers, proteins, sugars, DNA, RNA, cells, viruses, or other biomolecules for targeted delivery or recognition. Such labels or detectable moieties include but are not limited to organic and inorganic dyes, semiconducting nanoparticles (e.g. CdSe, CdS, CdSe/ZnS, ZnSe, PbSe nanoparticles), magnetic nanoparticles (e.g. Co, FePt, Fe3O4, Fe2O3 nanoparticles), or other metal nanoparticles (e.g. Au nanoparticles). For representative examples of nanoparticle PEGylation see Takae, S.; Akiyama, Y.; Otsuka, H.; Nakamura, T.; Nagasaki, Y.; Kataoka, K. “Ligand density effect on biorecognition by PEGylated gold nanoparticles: regulated interaction of RCA120 lectin with lactose installed to the distal end of tethered PEG strands on gold surface” Biomacromolecules 2005, 6, 818-824; Ishii, T.; Sunaga, Y.; Otsuka, H.; Nagasaki, Y.; Kataoka, K. “Preparation of water soluble CdS quantum dots stabilized by functional poly(ethylene glycol) and its application for bioassay” J. Photopolym. Sci. Technol. 2004, 17, 95-98; Otsuka, H.; Akiyama, Y.; Nagasaki, Y.; Kataoka, K. “Quantitative and Reversible Lectin-Induced Association of Gold Nanoparticles Modified with α-Lactosyl-ω-mercapto-poly(ethylene glycol)” J. Am. Chem. Soc. 2001, 123, 8226-8230; Åkerman, M. E.; Chan, W. C. W.; Laakkonen, P.; Bhatia, S, N.; Ruoslahti, E. R. “Nanocrystal targeting in vivo” P. Natl. Acad. Sci. USA 2002, 99, 12617-12621; Skaff, H.; Emrick, T. “A Rapid Route to Amphiphilic Cadmium Selenide Nanoparticles Functionalized with Poly(ethylene glycol)” Chem. Comm., 2003, 1, 52-53.


Accordingly, another aspect of the present invention provides a method of PEGylating a biomolecule with a compound of formula I as described generally above and in classes and subclasses defined above and herein. Thus, in certain embodiments, the present invention provides a biomolecule conjugated with a compound of the present invention. In certain embodiments, the present invention provides a method of PEGylating a therapeutic or a therapeutic carrier such as a protein, a cell, a virus particle, a plasmid, an oligopeptide, an oligonucleotide (e.g. siRNA, miRNA, aptamer), small molecule drug, a liposome, a polymersome, a polymer microshere, or a lipid emulsion with a compound of formula I as described generally above and in classes and subclasses defined above and herein. According to another aspect, the present invention provides a method for PEGylating a substrate. Such PEGylation may be carried out by covalent linking of a terminal PEG functionality to the substrate or using any number of bioconjugation techniques.


The bifunctional PEG's of the present invention are also useful for linking two biomolecules together wherein said biomolecules are the same or different from each other. For example, one terminus of the present compounds may be linked to a surface, another polymer, therapeutic, therapeutic carrier, protein, cell, virus particle, a plasmid, oligopeptide, oligonucleotide (e.g. siRNA, miRNA, aptamer), small molecule drug, liposome, polymersome, polymer microshere, lipid emulsion, or a detectable moiety and the other terminus of the present compounds may be linked to a surface, targeting group, permeation enhancer, growth factor, protein, sugar, DNA, RNA, cell, virus, diagnostic agent, or a detectable moiety. Accordingly, the present invention also provides a method for linking two biomolecules together wherein said method comprises coupling one terminus of a compound of formula I to a first biomolecule then coupling the other terminus of a compound of formula I to a second molecule, wherein the first and second biomolecules may be the same or different from each other.


Accordingly, one aspect of the present invention provides a method of PEGylating a protein therapeutic with a compound of formula I as described generally above and in classes and subclasses defined above and herein. Thus, in certain embodiments, the present invention provides a protein therapeutic conjugated with a compound of the present invention. Such PEGylation may be carried out by covalent linking of one PEG functionality to the protein using any number of bioconjugation techniques. The opposite PEG end group can be further linked to targeting groups, permeation enhancers, proteins, sugars, DNA, RNA, cells, viruses, dyes, detectable moieties, labels or other biomolecules for targeted delivery, biorecognition, or detection. For representative examples of PEGylating a protein see Harris, J. M.; Chess, R. B. “Effect of PEGylation on Pharmaceuticals” Nat. Rev. Drug. Discov. 2003, 2, 214-221; Kozlowski, A.; Harris, J. M. “Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C” J. Control. Release 2001, 72, 217-224; Koslowski, A.; Charles, S. A.; Harris, J. M. “Development of pegylated interferons for the treatment of chronic hepatitis C” Biodrugs 2001, 15, 419-429; Harris, J. M.; Martin, N. E.; Modi, M. “Pegylation: a novel process for modifying pharmacokinetics” Clin. Pharmacokinet. 2001, 40, 539-551; Roberts, M. J.; Bentley, M. D.; Harris, J. M. “Chemistry for peptide and protein PEGylation” Adv. Drug Deliver. Rev. 2002, 54, 459-476.


Another aspect of the present invention provides a method of PEGylating a small molecule drug with a compound of formula I as described generally above and in classes and subclasses defined above and herein. Thus, in certain embodiments, the present invention provides a small molecule drug conjugated with a compound of the present invention, also referred to as a “drug-polymer conjugate.” Such PEGylation may be carried out by covalent linking of one PEG functionality to the small molecule drug using any number of bioconjugation techniques. The opposite PEG end group can be further linked to targeting groups, permeation enhancers, proteins, sugars, DNA, RNA, cells, viruses, dyes, detectable moieties, labels or other biomolecules for targeted delivery, biorecognition, or detection. For representative examples of PEGylating a small molecule drug see Greenwald, R. B. “PEG drugs: an overview” J. Control. Release 2001, 74, 159-171; Caliceti, P.; Monfardini, C.; Sartore, L.; Schiavon, O.; Baccichetti, F.; Carlassare, F.; Veronese, F. M. “Preparation and properties of monomethoxy poly(ethylene glycol) doxorubicin conjugates linked by an amino acid or a peptide as spacer” Il Farmaco 1993, 48, 919-932; Fleming, A. B.; Haverstick, K.; Saltzman, W. M. “In vitro cytotoxicity and in vivo distribution after direct delivery of PEG-camptothecin conjugates to the rat brain” Bioconjug. Chem. 2004, 15, 1364-1375.


Yet another aspect of the present invention provides a drug-polymer conjugate comprising a compound of formula I and a pharmaceutically active agent. In still another aspect of the present invention, pharmaceutically acceptable compositions are provided, wherein these compositions comprise a drug-polymer conjugate as described herein, and optionally comprise a pharmaceutically acceptable carrier, adjuvant or vehicle. In certain embodiments, such compositions optionally further comprise one or more additional therapeutic agents.


One of ordinary skill in the art would recognize that the present compounds are useful for the PEGylation of small molecule drugs. Small molecule drugs suitable for PEGylation with the present compounds include, but are not limited to, those having a functional group suitable for covalently linking to the bifunctional PEG's of the present invention. Such drugs include, without limitation, chemotherapeutic agents or other anti-proliferative agents including taxanes (Taxol and taxotere derivatives), camptothecin, alkylating drugs (mechlorethamine, chlorambucil, Cyclophosphamide, Melphalan, Ifosfamide), antimetabolites (Methotrexate), purine antagonists and pyrimidine antagonists (6-Mercaptopurine, 5-Fluorouracil, Cytarabile, Gemcitabine), spindle poisons (Vinblastine, Vincristine, Vinorelbine, Paclitaxel), podophyllotoxins (Etoposide, Irinotecan, Topotecan), antibiotics (Doxorubicin, Bleomycin, Mitomycin), nitrosoureas (Carmustine, Lomustine), inorganic ions (Cisplatin, Carboplatin), enzymes (Asparaginase), angiogenesis inhibitors (Avastin) and hormones (Tamoxifen, Leuprolide, Flutamide, and Megestrol), Gleevec, dexamethasone, and cyclophosphamide. For a more comprehensive discussion of updated cancer therapies see, http://www.nci.nih.gov/, a list of the FDA approved oncology drugs at http://www.fda.gov/cder/cancer/druglistframe.htm, and The Merck Manual, Seventeenth Ed. 1999, the entire contents of which are hereby incorporated by reference.


Other examples of small molecule drugs that may be PEGylated with the compounds of this invention include treatments for Alzheimer's Disease such as Aricept® and Excelon®; treatments for Parkinson's Disease such as L-DOPA/carbidopa, entacapone, ropinrole, pramipexole, bromocriptine, pergolide, trihexephendyl, and amantadine; agents for treating Multiple Sclerosis (MS) such as beta interferon (e.g., Avonex® and Rebif®), Copaxone®, and mitoxantrone; treatments for asthma such as albuterol and Singulair®; agents for treating schizophrenia such as zyprexa, risperdal, seroquel, and haloperidol; anti-inflammatory agents such as corticosteroids, TNF blockers, IL-1 RA, azathioprine, cyclophosphamide, and sulfasalazine; immunomodulatory and immunosuppressive agents such as cyclosporin, tacrolimus, rapamycin, mycophenolate mofetil, interferons, corticosteroids, cyclophosphamide, azathioprine, and sulfasalazine; neurotrophic factors such as acetylcholinesterase inhibitors, MAO inhibitors, interferons, anti-convulsants, ion channel blockers, riluzole, and anti-Parkinsonian agents; agents for treating cardiovascular disease such as beta-blockers, ACE inhibitors, diuretics, nitrates, calcium channel blockers, and statins; agents for treating liver disease such as corticosteroids, cholestyramine, interferons, and anti-viral agents; agents for treating blood disorders such as corticosteroids, anti-leukemic agents, and growth factors; and agents for treating immunodeficiency disorders such as gamma globulin.


Another aspect of the present invention provides a method of PEGylating a virus with a compound of formula I as described generally above and in classes and subclasses defined above and herein. Thus, in certain embodiments, the present invention provides a virus conjugated with a compound of the present invention. Such PEGylation may be carried out by covalent linking of one PEG functionality to the virus using any number of bioconjugation techniques. The opposite PEG end group can be further linked to targeting groups, permeation enhancers, proteins, sugars, DNA, RNA, cells, viruses, dyes, detectable moieties, labels or other biomolecules for targeted delivery, biorecognition, or detection. For representative examples of virus PEGylation see Gupta, S. S.; Kuzelka, J.; Singh, P.; Lewis, W. G.; Manchester, M.; Finn, M. G. “Accelerated Bioorthogonal Conjugation: A Practical Method for the Ligation of Diverse Functional Molecules to a Polyvalent Virus Scaffold” Bioconjug. Chem. 2005, 16, 1572-1579; Raja, K. S.; Wang, Q.; Gonzalez, M. J.; Manchester, M.; Johnson, J. E.; Finn, M. G. “Hybrid Virus-Polymer Materials. 1. Synthesis and Properties of PEG-Decorated Cowpea Mosaic Virus” Biomacromolecules 2003, 4, 472-476; Oh, I. K.; Mok, H.; Park, T. G. “Folate Immobilized and PEGylated Adenovirus for Retargeting to Tumor Cells” Bioconjugate Chem. ASAP Article (Published online Apr. 14, 2006)


Yet another aspect of the present invention provides a method of PEGylating therapeutic carriers such as liposomes, polymersomes, microspheres, capsules, or lipid emulsions with a compound of formula I as described generally above and in classes and subclasses defined above and herein. Thus, in certain embodiments, the present invention provides a therapeutic carrier conjugated with a compound of the present invention. Such PEGylation may be carried out by covalent linking of one PEG functionality to the therapeutic carrier using any number of bioconjugation techniques or by the non-covalent incorporation of a PEGylated molecule (e.g. lipid, phospholipid, or polymer) into the carrier. The opposite PEG end group can be further linked to targeting groups, permeation enhancers, proteins, sugars, DNA, RNA, cells, viruses, dyes, detectable moieties, labels or other biomolecules for targeted delivery, biorecognition, or detection. For representative examples of PEGylating therapeutic carriers see Lukyanov, A. N.; Elbayoumi, T. A.; Chakilam, A. R.; Torchilin, V. P. “Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody” J. Control. Release 2004, 100, 135-144; Forssen, E.; Willis, M. “Ligand-targeted liposomes” Adv. Drug Del. Rev. 1998, 29, 249-271; Koning, G. A.; Schiffelers, R. M.; Wauben, M. H. M.; Kok, R. J.; Mastrobattista, E.; Molema, G.; ten Hagen, T. L. M.; Storm, G. “Targeting of Angiogenic Endothelial Cells at Sites of Inflammation by Dexamethasone Phosphate-Containing RGD Peptide Liposomes Inhibits Experimental Arthritis” Arthritis Rheum. 2006, 54, 1198-1208; Torchilin, V. P. “Structure and design of polymeric surfactant-based drug delivery systems” J. Control. Release 2001, 73, 137-172.


Another aspect of the present invention provides a method of PEGylating a cell with a compound of formula I as described generally above and in classes and subclasses defined above and herein. Thus, in certain embodiments, the present invention provides a cell conjugated with a compound of the present invention. Such PEGylation may be carried out by covalent linking of one PEG functionality to the cell using any number of bioconjugation techniques. The opposite PEG end group can be further linked to targeting groups, permeation enhancers, proteins, sugars, DNA, RNA, cells, viruses, dyes, detectable moieties, labels or other biomolecules for targeted delivery, biorecognition, or detection. See Scott, M. D.; Chen, A. M. “Beyond the red cell: pegylation of other blood cells and tissues” Transfus. Clin. Biol. 2004, 11, 40-46.


Another aspect of the present invention provides a method of PEGylating the surface of a natural or synthetic material or biomaterial with a compound of formula I as described generally above and in classes and subclasses defined above and herein. Thus, in certain embodiments, the present invention provides a surface conjugated with a compound of the present invention. Such PEGylation may be carried out by covalent linking of one PEG functionality to the surface using any number of bioconjugation techniques or through non-covalent interactions with PEG or the PEG end-groups. Such surface PEGylation generally enhances anti-fouling properties of the material and can reduce the foreign-body response of injectable or implantable biomaterials. For representative examples of Bergström, K.; Holmberg, K.; Safranj, A.; Hoffman, A. S.; Edgell, M. J.; Kozlowski, A.; Hovanes, B. A.; Harris, J. M. “Reduction of fibrinogen adsorption on PEG-coated polystyrene surfaces” J. Biomed. Mater. Res. 1992, 26, 779-790; Vladkova, T.; Krasteva, N.; Kostadinova, A.; Altankov, G. “Preparation of PEG-coated surfaces and a study for their interaction with living cells” J. Biomater. Sci. Polym. Ed. 1999, 10, 609-620.


Another aspect of the present invention provides a method of linking molecules or biomolecules to a synthetic or natural surface with a compound of formula I as described generally above and in classes and subclasses defined above and herein. Such PEGylation may be carried out by covalent linking of one PEG functionality to the surface using any number of bioconjugation techniques or through non-covalent interactions with PEG or the PEG end-groups. The opposite PEG end group can be further linked to proteins, sugars, DNA, RNA, cells, viruses, dyes, detectable moieties, labels or other biomolecules for biorecognition and/or detection. For representatives examples of using PEGylated surface linkers see Otsuka, H.; Nagasaki, Y.; Kataoka, K. “Characterization of aldehyde-PEG tethered surfaces: influence of PEG chain length on the specific biorecognition” Langmuir 2004, 20, 11285-11287; Muñoz, E. M.; Yu, H.; Hallock, J.; Edens, R. E.; Linhardt, R. J. “Poly(ethylene glycol)-based biosensor chip to study heparin-protein interactions” Anal. Biochem. 2005, 343, 176-178; Metzger, S. W.; Natesan, M.; Yanavich, C.; Schneider, J.; Leea, G. U. “Development and characterization of surface chemistries for microfabricated biosensors” J. Vac. Sci. Technol. A 1999, 17, 2623-2628; Hahn, M. S.; Taite, L. J.; Moon, J. J.; Rowland, M. C.; Ruffino, K. A.; West, J. L. “Photolithographic patterning of polyethylene glycol hydrogels” Biomaterials 2006, 27, 2519-2524; Veiseh, M.; Zareie, M. H.; Zhang, M. “Highly Selective Protein Patterning on Gold-Silicon Substrates for Biosensor Applications” Langmuir, 2002, 18, 6671-6678.


Another aspect of the present invention provides a method of incorporating PEG into a hydrogel with a compound of formula I as described generally above and in classes and subclasses defined above and herein. Thus, in certain embodiments, the present invention provides a hydrogel conjugated with a compound of the present invention. Such PEGylation may be carried out by the reaction of one PEG functionality for incorporation into the hydrogel matrix or through non-covalent interaction of the hydrogel and PEG or the PEG end-groups. The opposite PEG end group can be further linked to proteins, growth factors, antibodies, oligopeptides, sugars, DNA, RNA, cells, viruses, dyes, detectable moieties, labels or other biomolecules to promote cell adhesion and growth, for biorecognition, or detection. For examples of producing hydrogels from functional PEGs see Kim, P.; Kim, D. H.; Kim, B.; Choi, S. K.; Lee, S. H.; Khademhosseini, A.; Langer, R.; Suh, K. Y. “Fabrication of nanostructures of polyethylene glycol for applications to protein adsorption and cell adhesion” Nanotechnology, 2005, 16, 2420-2426; Raeber, G. P.; Lutolf, M. P; Hubbell, J. A. “Molecularly Engineered PEG Hydrogels: A Novel Model System for Proteolytically Mediated Cell Migration” Biophys. J. 2005, 89, 1374-1388; Quick, D. J.; Anseth, K. S. “DNA delivery from photocrosslinked PEG hydrogels: encapsulation efficiency, release profiles, and DNA quality” J. Control. Release 2004, 96, 341-351.


Another aspect of the present invention provides a method of producing block and graft copolymers of PEG using a compound of formula I as described generally above and in classes and subclasses defined above and herein. Thus, in certain embodiments, the present invention provides a block or graft copolymer comprising a compound of the present invention. PEGs of formula I which possess appropriate reactive functionality may serve as macroinitiators of cyclic esters (e.g. caprolactone, lactide, glycolide), cyclic ethers, cyclic phosphazenes, N-carboxyanhydrides (NCAs), or vinyl monomers (e.g. N-isopropylacrylamide, methyl acrylate, styrene) to synthesize block copolymers for use as micellar therapeutic carriers. One or both PEG functionalities can be used to initiate or mediate the growth of additional polymer blocks. In cases where a single PEG functionality serves as an initiator, the opposite PEG end group can be further linked to targeting groups, permeation enhancers, proteins, sugars, DNA, RNA, cells, viruses, dyes, detectable moieties, labels or other biomolecules for targeted delivery, biorecognition, or detection. For representative examples of PEG macroinitiators see Akiyama, Y.; Harada, A.; Nagasaki, Y.; Kataoka, K. Macromolecules 2000, 33, 5841-5845; Yamamoto, Y.; Nagasaki, Y.; Kato, Y.; Sugiyama, Y.; Kataoka, K. “Long-circulating poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles with modulated surface charge” J. Control. Release 2001, 77, 27-38; Bae, Y.; Jang, W. D.; Nishiyama, N.; Fukushima, S.; Kataoka, K. “Multifunctional polymeric micelles with folate-mediated cancer cell targeting and pH-triggered drug releasing properties for active intracellular drug delivery” Mol. Biosyst. 2002, 1, 242-250; Nasongkla, N.; Shuai, X.; Ai, H.; Weinberg, B. D.; Pink, J.; Boothman, D. A.; Gao, J. “cRGD-Functionalized Polymer Micelles for Targeted Doxorubicin Delivery” Angew. Chem. Int. Ed. 2004, 43, 6323-6327.


As described above, the pharmaceutically acceptable compositions of the present invention additionally comprise a pharmaceutically acceptable carrier, adjuvant, or vehicle, which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various carriers used in formulating pharmaceutically acceptable compositions and known techniques for the preparation thereof. Except insofar as any conventional carrier medium is incompatible with the compounds of the invention, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutically acceptable composition, its use is contemplated to be within the scope of this invention.


Some examples of materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, wool fat, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil; glycols; such a propylene glycol or polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator.


The compounds and compositions, according to the method of the present invention, may be administered using any amount and any route of administration effective for treating or lessening the severity of the disorder being treated. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular agent, its mode of administration, and the like. The compounds of the invention are preferably formulated in dosage unit form for ease of administration and uniformity of dosage. The expression “dosage unit form” as used herein refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific effective dose level for any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts. The term “patient”, as used herein, means an animal, preferably a mammal, and most preferably a human.


The pharmaceutically acceptable compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated. In certain embodiments, the compounds of the invention may be administered orally or parenterally at dosage levels of about 0.01 mg/kg to about 50 mg/kg and preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.


EXAMPLES

As depicted in the Examples below, in certain exemplary embodiments, compounds are prepared according to the following general procedures. It will be appreciated that, although the general methods depict the synthesis of certain compounds of the present invention, the following general methods, in addition to the Schemes set forth above and other methods known to one of ordinary skill in the art, can be applied to all compounds and subclasses and species of each of these compounds, as described herein. Each compound number referenced below corresponds to compound numbers recited in Tables 1 through 25, supra.


General Methods


Method A: Polymerization


To a stirred solution of initiator (1 mmol) in anhydrous THF (100 mL) was added a solution of potassium naphthalenide in THF (0.2 M, 5 mL, 1 mmol). The resulting solution was then cooled to 0° C. Ethylene oxide (10 g, 227 mmol) was introduced to the alkoxide solution using Schlenk techniques. Upon complete addition of the ethylene oxide, the flask was backfilled with Argon, sealed and stirred at room temperature for 24 h. At this point, additional terminating agents were added or the reaction was quenched with water and methanol followed by the removal of solvent under reduced pressure.


Method B: Purification by Solid Phase Extraction


The viscous liquid containing the desired polymer was loaded onto 100 g silica gel which was rinsed with 3% MeOH in CHCl3 (1 L) followed by 10% MeOH in CHCl3 (1 L) which contained the polymer product. The solvent was removed and the resulting liquid was diluted with a minimal amount of methanol and precipitated into diethyl ether. A white powder was isolated following filtration.


Method C: Purification by Liquid Extraction


The viscous liquid containing the desired polymer was dissolved in 100 mL water then extracted with CHCl3 (4×300 mL). The combined organic layers dried over MgSO4, and filtered. The solvent was removed and the resulting liquid was diluted with a minimal amount of methanol and precipitated in to diethyl ether. A white powder was isolated following filtration.


Method D: Removal of Benzyl Protecting Groups


To a 250 mL round bottom flask was added 10% palladium hydroxide on carbon (0.6 g) and methanol (50 mL). Dibenzylamino-polyethylene glycol (10 g) and ammonium formate (2 g) was added and the reaction heated to reflux for 16 hours. The solution was cooled, diluted with chloroform (100 mL) then filtered over celite, then the solvent removed. The resulting liquid was dissolved in 1 N sodium hydroxide and purified according to Method C.


Method E: Application of the BOC Protecting Group


To a 250 mL round bottom flask was added amino-polyethylene glycol-alcohol (10 g) and methanol (150 mL). Di-t-butyldicarbonate (10 equiv) and DMAP (1 equiv) was added and the resulting solution stirred at room temperature. The solvent was removed and purified according to Method B.


Method F: Mitsunobu Coupling


The desired PEG derivative (1 equiv) was dissolved in dichloromethane (˜10 mL/g PEG). Triphenylphosphine (4 equiv) followed by the desired Mitsunobu terminating agent (5 equiv) then DIAD (3 equiv) was added to the solution then stirred for 8 hours. The solvent was removed and purified according to Method B.


Method G: Mesylation


The desired PEG derivative (1 equiv) was dissolved in CH2Cl2 (˜10 mL/g PEG), and cooled to 0° C. Methanesulfonyl chloride (2 equiv) was added dropwise via syringe under nitrogen followed by addition of triethylamine (2.5 equiv). The solution was warmed to room temperature and stirred for 12 hours. The solvent was removed and the product used as is or was optionally further purified by Method B.


Method H: Azide Functionalization


The desired PEG derivative (1 equiv) was dissolved in ethanol (˜10 mL/g PEG), and then NaN3 (10 equiv) was added. The solution was stirred at reflux for 16 hours, allowed to cool, the solvent evaporated and purified by Method B.


Method I: Removal of the BOC Protecting Group


The desired PEG (1 g) was dissolved in a minimal amount of THF (2 mL) and stirred at room temperature. HCl in dioxane (4M, 5 mL) was added and the solution stirred under Argon for 6 hours. The solution was poured into cold diethyl ether and the polymer product obtained as a white powder following filtration.


Method J: Removal of the Oxazoline Protecting Group


The desired PEG (1 g) was dissolved in 10 mL of 3 N HCl (aq) and stirred at reflux for 4 hours. The solution was cooled and purified according to Method C.


Method K: Application of the Trifluoracetamide Group


The desired amino-PEG derivative (1 equiv) was dissolved in methanol ((˜10 mL/g PEG). Ethyl trifluoracetate (3 equiv) was added and the resulting solution stirred at room temperature for 16 h. The solvent was removed and purified according to Method B.


Method L: Removal of the THP protecting group


The desired PEG derivative (1 equiv) was dissolved in ethanol (˜10 mL/g PEG), and then pyridinium para-toluene sulfonate (PPTS) (3 equiv) was added. The solution was stirred at reflux for 16 hours, allowed to cool, the solvent evaporated and purified by Method C.


Method M: Removal of the Furan Protecting Group


The desired PEG derivative was dissolved in toluene (˜10 mL/g PEG) and refluxed for 4 hours. After allowing the solution to cool, the polymer was precipitated in to diethyl ether. A white powder was isolated following filtration.


Example 1



embedded image


Dibenzylamino-poly(ethylene glycol)-alcohol was prepared according to Method A and purified according to Method B in 80% yield. 1H NMR (400 MHz, DMSO-d6, δ) 7.4-7.2 (m, Ar—H), 4.63 (t, CH2OH), 3.7-3.3 (br-m, —O—CH2—CH2—O—). GPC (DMF, PEG standards) Mn=10,800; PDI=1.10.


Example 2



embedded image


Amino-poly(ethylene glycol)-alcohol was prepared according to Method D in 84% yield. 1H NMR (400 MHz, DMSO-d6, δ) 3.7-3.3 (br-m, —O—CH2—CH2—O—), 2.62 (m, —CH2—NH2).


Example 3



embedded image


Boc-amino-poly(ethylene glycol)-alcohol was prepared according to Method E in 89% yield. 1H NMR (400 MHz, DMSO-d6, δ) 6.82 (br-s, CH2—NH—CO—), 4.63 (t, CH2OH), 3.7-3.3 (br-m, —O—CH2—CH2—O), 1.40 (s, —C—(CH3)3). GPC (DMF, PEG standards) Mn=10,100; PDI=1.06.


Example 4



embedded image


Dibenzylamino-poly(ethylene glycol)-diethylphosphonate was prepared according to Method A. After 24 h, vinyl-diethylphosphonate (0.82 g, 5 mmol) was added to the reaction using Schlenk techniques. The solution was stirred for and additional 12 h at 40° C., allowed to cool, and the solvent removed. The resulting viscous liquid was purified by solid phase extraction (The liquid was loaded onto 300 mL silica gel which was rinsed with 3% MeOH in CHCl3 (1 L) followed by 10% MeOH in CHC3 (1 L) which contained the polymer product) then precipitation into cold diethyl ether to give a white powder (7.4 g, 73% yield). 1H NMR (400 MHz, DMSO-d6, δ) 7.3-7.2 (m, Ar—H), 4.01 (m, CH3—CH2—O), 3.7-3.3 (br-m, —O—CH2—CH2—) 2.55 (s, Ar—CH2—N), 1.24 (m, CH3—CH2—O). GPC (THF, PEG standards) Mn=7,700; PDI=1.05.


This compound is debenzylated according to Method D to form Compound 246.


Example 5



embedded image


Dibenzylamino-poly(ethylene glycol)-diethylphosphonate (1 g, 0.33 mmol) was dissolved in anhydrous methylene chloride (10 mL). TMS-Br (0.17 mL, 1.3 mmol) was added via syringe and the resulting solution stirred at room temperature for 16 hours. The reaction was quenched with water (1 mL, 55 mmol) then the solution precipitated into cold diethyl ether. The product was obtained as a white powder following filtration (0.85 g, 85% yield). 1H NMR (400 MHz, DMSO-d6, δ) 7.58, 7.47, 3.94, 3.7-3.3, 2.69.


This compound is debenzylated according to Method D to form Compound 248.


Example 6



embedded image


Tetrahydropyran-poly(ethylene glycol)-propyne was prepared according to Method A. After 24 h, propargyl bromide (3.9 g, 33 mmol) was added to the reaction using Schlenk techniques. The solution was stirred for and additional 12 h at 40° C., allowed to cool, and the solvent removed. The residue was purified according to Method B in 74% yield. 1H NMR (400 MHz, DMSO-d6, δ) 4.55, 4.14, 3.7-3.3, 1.71, 1.61, 1.46. GPC (THF, PEG standards) Mn=2,400; PDI=1.04.


Example 7



embedded image


Azido-poly(ethylene glycol)-alcohol was prepared according to Method A followed by Method B in 80% yield. 1H NMR (400 MHz, DMSO-d6, δ) 4.57 (t, CH2OH), 3.7-3.3 (br-m, —O—CH2—CH2—). GPC (THF, PEG standards) Mn=9,500; PDI=1.05.


Example 8



embedded image


t-Butyldiphenylsilylpropargyl-poly(ethylene glycol) was prepared according to Method A followed by Method B in 59% yield. 1H NMR (400 MHz, DMSO-d6, δ) 7.62 (m, Ar—H), 7.41 (m, Ar—H), 4.55 (t, CH2OH), 3.7-3.3 (br-m, —O—CH2—CH2—O—), 0.91 (s, t-butyl). GPC (THF, PEG standards) Mn=2,700; PDI=1.17.


Example 9



embedded image


Dibenzylamino-poly(ethylene glycol)-benzoic acid benzyl ester was prepared according to Method A followed by Method F in 74% yield. 1H NMR (400 MHz, DMSO-d6, δ) 7.95, 7.6-7.2, 7.05, 4.15, 3.75, 3.6-3.3, 2.55. GPC (THF, PEG standards) Mn=1,800; PDI=1.06.


Example 10



embedded image


Amino-poly(ethylene glycol)-benzoic acid (Compound 228) was prepared according to Method D in 74% yield. 1H NMR (400 MHz, DMSO-d6, δ) 7.9, 7.1, 3.7-3.3.


Example 11



embedded image


Dibenzylamino-polyethylene glycol-phthalimide was prepared according to Method A followed by Method F in 73% yield. 1H NMR (400 MHz, DMSO-d6, δ) 7.85 (m, phthalimide Ar—H), 7.4-7.2 (m, Ar—H), 3.7-3.3 (br-m, —O—CH2—CH2—O—). GPC (DMF, PEG standards) Mn=10,900; PDI=1.11.


Example 12



embedded image


Amino-polyethylene glycol-phthalimide was prepared according to Method D in 63% yield. 1H NMR (400 MHz, DMSO-d6, δ) 7.87, 7.32, 3.7-3.3, 2.66.


Example 13



embedded image


Hexyne-polyethylene glycol-BOC-aminophenoxy ether was prepared according to Method A followed by Method F in 70% yield. 1H NMR (400 MHz, DMSO-d6, δ) 7.85 (m, phthalimide Ar—H), 7.35 (d, Ar—H), 6.85 (d, Ar—H), 3.7-3.3 (br-m, —O—CH2—CH2—O—), 2.14 (m, —CH2), 1.73 (t, CH3), 1.61 (q, —CH2), 1.39 (s, —C—(CH3)3). GPC (DMF, PEG standards) Mn=10,800; PDI=1.10.


Example 14



embedded image


Hexyne-polyethylene glycol-amine hydrochloride phenoxy ether was prepared according to Method I in 87% yield. 1H NMR (400 MHz, DMSO-d6, δ) 8.4 (br-s) 7.80 (m, phthalimide Ar—H), 7.37 (d, Ar—H), 6.85 (d, Ar—H), 3.7-3.3 (br-m, —O—CH2—CH2—O—), 2.13 (m, —CH2), 1.73 (t, CH3), 1.61 (q, —CH2).


Example 15



embedded image


Tetrahydropyran-poly(ethylene glycol)-phosphonic ester was prepared according to Method A. After 24 h, vinyl diethyl phosphonate (3.2 g, 20 mmol) was added to the reaction using Schlenk techniques. The solution was stirred for and additional 12 h at 40° C., allowed to cool, and the solvent removed and purified by Method B in 70% yield. 1H NMR (400 MHz, DMSO-d6, δ) 4.01, 3.3-3.7, 2.06, 1.71, 1.58, 1.45, 1.22, 1.09. GPC (DMF, PEG standards) Mn=6,700; PDI=1.05.


The THP group is removed according to Method A to form Compound 119.


The phosphonic ester is hydrolyzed according to Example 5 to form Compound 120.


Example 16



embedded image


BOC-aminopolyethylene glycol-propargyl phenoxy ether was prepared according to Method F in 66% yield. 1H NMR (400 MHz, DMSO-d6, δ) 7.62 m, 7.56 m, 6.89 t, 4.70 s, 4.03 t, 3.3-3.7 bm, 3.03 q, 1.37 s. GPC (DMF, PEG standards) Mn=7,000; PDI=1.02.


The BOC group is removed according to Method I to form the free amino compound.


Example 17



embedded image


BOC-amino-polyethylene glycol-azide (Compound 257) was prepared according to Method G followed by Method H in 66% yield. 1H NMR (400 MHz, DMSO-d6, δ) 6.84 t, 3.3-3.7 bm, 1.37 s. GPC (DMF, PEG standards) Mn=7,400; PDI=1.02.


Example 18



embedded image


TBDMS-PEG-alcohol was prepared according to Method A in 78% yield. 1H NMR (400 MHz, DMSO-d6, δ) 4.55 t, 3.3-3.7 bm, 0.83 s, 0.09 s. GPC (DMF, PEG standards) Mn=2,400; PDI=1.02.


Example 19



embedded image


THP-PEG-phosphonic acid was prepared according to Method A. POCl3 (5 equiv) was added and stirred for 6 h at room temperature. The solvent was removed and the residue purified according to Method C giving 62% yield. GPC (DMF, PEG standards) Mn=4,100; PDI=1.43.


Example 20



embedded image


THP-PEG-azide was prepared according to Method G followed by Method H in 92% yield. GPC (DMF, PEG standards) Mn=2,400; PDI=1.01. 1H NMR (400 MHz, DMSO-d6, δ) 3.3-3.7 bm, 1.71 m, 1.60 m, 1.44 m. 1.18 m.


Example 21



embedded image


Oxazoline-PEG-OH was prepared according to Method A followed by Method B in 49% yield. 1H NMR (400 MHz, DMSO-d6, δ) 4.14 t, 3.3-3.7 bm, 2.24 t, 1.75 quint. GPC (DMF, PEG standards) Mn=4,850; PDI=1.04.


Example 22



embedded image


Carboxylic acid-PEG-OH was prepared according to Method J in 82% yield. 1H NMR (400 MHz, DMSO-d6, δ) 4.55 t, 3.3-3.7 bm, 2.24 t, 2.13 t, 1.71 quint.


Example 23



embedded image


Oxazoline-PEG-Oxanorbornene was prepared by Method F in 76% yield. 1H NMR (400 MHz, DMSO-d6, δ) 6.59 s, 5.12 s, 4.15 t, 3.3-3.7 bm, 2.94 s, 2.22 t, 1.75 quint. GPC (DMF, PEG standards) Mn=5,100; PDI=1.04.


Example 24



embedded image


Carboxylic acid-PEG-oxanorbornene was prepared according to Method J in 90% yield. 1H NMR (400 MHz, DMSO-d6, δ) 6.59 s, 5.12 s, 3.3-3.7 bm, 2.94 s, 2.24 t, 2.13 t, 1.71 quint. GPC (DMF, PEG standards) Mn=5,100; PDI=1.04.


Example 25



embedded image


Trifluoroacetamide-PEG-alcohol was prepared according to Method K in 73% yield. 1H NMR (400 MHz, DMSO-d6, δ) 4.55 t, 3.3-3.7 bm. GPC (DMF, PEG standards) Mn=5,000; PDI=1.07.


Example 26



embedded image


Azido-PEG-alcohol was prepared according to Method L in 84% yield. 1H NMR (400 MHz, DMSO-d6, δ) 4.55 t, 3.3-3.7 bm. GPC (DMF, PEG standards) Mn=5,200; PDI=1.03.


Example 27



embedded image


Propargyl-PEG-alcohol was prepared according to Method L in 87% yield. 1H NMR (400 MHz, DMSO-d6, δ) 4.55 t, 4.14 d, 3.3-3.7 bm. GPC (DMF, PEG standards) Mn=5,400; PDI=1.03.


Example 28



embedded image


THP-PEG-oxanorbornene was prepared according to Method F in 97% yield. 1H NMR (400 MHz, DMSO-d6, δ) 6.55 s, 5.12 s, 4.57 t, 3.3-3.7 bm, 2.92 s, 1.71 m, 1.60 m, 1.44 m. 1.18 m.


Example 29



embedded image


Alcohol-PEG-oxanorbornene was prepared according to Method L in 55% yield. 1H NMR (400 MHz, DMSO-d6, δ) 6.55 s, 5.12 s, 4.55 t, 3.3-3.7 bm, 2.94 s.


Example 30



embedded image


Carboxylic acid-PEG-maleimide (compound 18) was prepared according to Method L in 90% yield. 1H NMR (400 MHz, DMSO-d6, δ) 11.94 bs, 7.02 s, 3.3-3.7 bm, 2.24 t, 1.70 t. GPC (DMF, PEG standards) Mn=2,200; PDI=1.05.


Example 31



embedded image


NHS-Ester-PEG-maleimide was prepared by dissolving PEG (1 equiv) and N-hydroxysuccinimide (5 equiv) in methylene chloride (˜10 mL/g PEG). DCC (5 equiv) was then added and the solution stirred at room temperature for 12 hours. The solution was filtered and the solvent removed. The residue was dissolved in isopropanol and precipitated into diethyl ether, filtered, redissolved in isopropanol and precipitated again into diethyl ether. A white powder was isolated following filtration in 60% yield. 1H NMR (400 MHz, DMSO-d6, δ) 7.02 s, 3.3-3.7 bm, 2.81 s, 2.70 t, 1.84 t. GPC (DMF, PEG standards) Mn=2,600; PDI=1.05.


Example 32



embedded image


Azido-PEG-amine hydrochloride was prepared according to Method I in 88% yield. 1H NMR (400 MHz, DMSO-d6, δ) 7.86, 3.3-3.7, 2.71.


Example 33



embedded image



Azido-PEG-Amine


Boc-PEG-azide (5 g) was dissolved in methanol (50 mL) and stirred at room temperature until homogeneous. Anhydrous HCl was bubbled through the reaction for 5 minutes and the reaction stirred for an additional 15 minutes. The solvent was evaporated, dissolved in saturated NaHCO3 (30 mL, aqueous), then the product extracted with dichloromethane (3×60 mL). The combined organic layers were dried over MgSO4, and filtered. The solvent was removed and the resulting liquid was diluted with a minimal amount of methanol and precipitated in to diethyl ether. A white powder (4.5 g, 90% yield) was isolated following filtration. 1H NMR (400 MHz, DMSO-d6, δ) 3.3-3.7, 2.71. IR (cm−1) 3383, 2781, 2102, 1466, 1341, 1279, 1241, 1145, 1101, 1060, 956, 841.


While we have described a number of embodiments of this invention, it is apparent that our basic examples may be altered to provide other embodiments that utilize the compounds and methods of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the appended claims rather than by the specific embodiments that have been represented by way of example.

Claims
  • 1. A compound selected from any of the following, wherein each n is independently 10-2500:
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a Continuation of U.S. patent application Ser. No. 12/707,459, filed May 29, 2009; which is a Continuation of U.S. patent application Ser. No. 12/475,017, filed May 29, 2009, now U.S. Pat. No. 7,893,277 issued on Feb. 22, 2011; which is a Continuation of U.S. patent application Ser. No. 11/796,385, filed Apr. 27, 2007, now U.S. Pat. No. 7,560,588, issued Jul. 14, 2009, which claims priority to U.S. provisional patent application Ser. No. 60/795,412, filed Apr. 27, 2006, the entirety of each of which is hereby incorporated herein by reference.

US Referenced Citations (42)
Number Name Date Kind
2832795 Hempel et al. Apr 1958 A
3352838 Toepfl et al. Nov 1967 A
4847325 Shadle et al. Jul 1989 A
5455027 Zalipsky et al. Oct 1995 A
5686110 Greenwald et al. Nov 1997 A
5756593 Martinez et al. May 1998 A
5808096 Zalipsky Sep 1998 A
5824701 Greenwald et al. Oct 1998 A
6127355 Greenwald et al. Oct 2000 A
6180095 Greenwald et al. Jan 2001 B1
6251382 Greenwald et al. Jun 2001 B1
6448369 Bentley et al. Sep 2002 B1
6608076 Greenwald et al. Aug 2003 B1
6649778 Zhao et al. Nov 2003 B1
6703446 Schwinderman et al. Mar 2004 B2
6720391 Schwinderman et al. Apr 2004 B2
6737505 Bentley et al. May 2004 B2
6777387 Greenwald et al. Aug 2004 B2
6894025 Harris May 2005 B2
6899867 Bentley et al. May 2005 B2
7026440 Bentley et al. Apr 2006 B2
7033583 Choe et al. Apr 2006 B2
7230068 Wilson Jun 2007 B2
7737226 Wilson Jun 2010 B2
7820766 Wilson Oct 2010 B2
8008428 Wilson Aug 2011 B2
20040116649 Kozlowski Jun 2004 A1
20050031576 McManus et al. Feb 2005 A1
20050036978 Kozlowski Feb 2005 A1
20050054816 McManus et al. Mar 2005 A1
20050119193 Motoyama Jun 2005 A1
20050214250 Harris et al. Sep 2005 A1
20060142506 Breitenkamp et al. Jun 2006 A1
20060172914 Breitenkamp et al. Aug 2006 A1
20060240092 Breitenkamp et al. Oct 2006 A1
20080035243 Breitenkamp et al. Feb 2008 A1
20080188638 Breitenkamp et al. Aug 2008 A1
20080207913 Breitenkamp et al. Aug 2008 A1
20080274173 Sill et al. Nov 2008 A1
20080274965 Skaff et al. Nov 2008 A1
20080280998 Bonora et al. Nov 2008 A1
20110269974 Wilson Nov 2011 A1
Foreign Referenced Citations (4)
Number Date Country
2005033181 Apr 2005 WO
2006086325 Aug 2006 WO
2008134734 Nov 2008 WO
2008134761 Nov 2008 WO
Non-Patent Literature Citations (23)
Entry
Li et al. CAS: 144: 114130, 2005.
Sakurai et al. CAS: 120:135468, 1994.
International Search Report, PCT/US2008/010462.
Akiyama, et al., “Selective synthesis of heterobifunctional poly(ethylene glycol) derivatives containing both mercapto and acetal terminals,” Bioconjugate Chem. 11:947-950, 2000.
Akiyama, et al., “Synthesis of heterotelechelic poly(ethylene glycol) derivatives having a-benzaldehyde and w-pyridyl disulfide groups by ring opening polymerization of ethylene oxide using 4-(diethoxymethyl)benzyl alkoxide as a novel initiator,” Bioconjugate Chem. 15: 424-427, 2004.
Akiyama, et al., “Synthesis of poly(ethylene glycol)-block-poly(ethylenimine) possessing an acetal group at the PEG end,” Macromolecules 33: 5841-5845, 2000.
Bettinger, et al., “Convenient polymer-supported synthetic route to heterobifunctional polyethylene Ggycols,” Bioconjugate Chem. 9: 842-846, 1998.
Cammas, et al., “Heterobifunctional poly(ethylene oxide): Synthesis of a-hydroxy-w-amino PEOs with the same molecular weights,” Bioconjugate Chem. 6: 226-230, 1995.
Glaied, et al., “Oxazoline-terminated macromonomers by the alkylation of 2-methyl-2-oxazoline,” Journal of Polymer Science: Part A: Polymer Chem. 43: 2440-2447, 2005.
Heroguez, et al., “Synthesis of a-norbornenylpoly(ethylene oxide) macromonomers and their ring-opening metathesis polymerization,” Macromolecules 29(13): 4459-4464, 1996.
Kazanskii, et al., “Strictly monofunctional methyl ethers of poly(ethylene glycol) and the related methacrylate macromonomers,” Polymer Science Ser. A. 43(6): 585-595, 2000.
Kim, et al., “Heterobifunctional poly(ethylene oxide),” Polymer Bulletin, 33: 1-6, 1994.
Li and Kao, “Synthesis of polyethylene glycol (PEG) derivatived and PEGylated—peptide biopolymer conjugates,” Biomacromolecules 4: 1055-1067, 2003.
Mongondry, et al., “Mild synthesis of amino-poly(ethylene glycol)s. Application to steric stabilization of clays,” Macromol. Rapid Commun. 24: 681-685, 2003.
Nagasaki, et al., “Primary amino-terminal heterobifunctional poly(ethylene oxide). Facile synthesis of poly(ethylene oxide) with a primary amino group at one end and a hydroxyl group at the other end,” Bioconjugate Chem. 6: 702-704, 1995.
Nagasaki, et al., “Synthesis of heterotelechelic poly(ethylene glycol) macromonomers. Preparation of poly(ethylene glycol) possessing a methacryloyl group at one end and a formyl group at the other end,” Macromolecules 30: 4689-6493, 1997.
Nakamura, et al., “Synthesis of heterobifunctional poly(ethylene glycol) with a reducing monosaccharide residue at one end,” Bioconjugate Chem. 9: 300-303, 1998.
Reed and Janda, “A one-step synthesis of monoprotected polyethylene glycol ethers,” J. Org. Chem., 65: 5843-5845, 2000.
Ryoo, et al., “Efficient methods of converting hydroxyl groups into amino groups in poly(ethylene glycol)-grafted polystyrene resin,” Journal of Combinatorial Chem. 4(3): 187-190, 2002.
Senyo, et al., “Syntheses of poly(ethylene oxide) macromonomers carry tertiary amine and quaternary ammonium end groups,” Polymer Journal 35(6): 513-518, 2003.
Shen, et al., “One-step synthesis of a-p-vinylphenylalkyl-w-hydroxy poly(ethylene oxide) macromonomers by anionic polymerization initiated from p-vinylphenylalkanols,” Polymer 44: 3221-3228, 2003.
Zhang, et al., “Synthesis of heterobifunctional poly(ethylene glycol) with a primary amino group at one end and a carboxylate group at the other end,” Reactive & Functional Polymers 56: 17-25, 2003.
Hiki, et al., “A facile synthesis of azido-terminated heterobifunctional poly(ethyleneglycol)s for ‘click’ conjugation,” Bioconjugate Chem. 18: 2191-2196, 2007.
Related Publications (1)
Number Date Country
20120226050 A1 Sep 2012 US
Continuations (3)
Number Date Country
Parent 12707459 Feb 2010 US
Child 13471064 US
Parent 12475017 May 2009 US
Child 12707459 US
Parent 11796385 Apr 2007 US
Child 12475017 US